

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037346 A1

(51) International Patent Classification⁷: **A61K 31/53**,
C07D 251/18, 251/16, 251/22, 405/12, 403/12

(74) Agents: **SHARKEY, Richard, G.** et al.; Seed Intellectual
Property Law Group PLLC, Suite 6300, 701 Fifth Avenue,
Seattle, WA 98104-7092 (US).

(21) International Application Number: PCT/US02/35256

(22) International Filing Date: 30 October 2002 (30.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/330,772 31 October 2001 (31.10.2001) US

(71) Applicant (for all designated States except US): **CELL
THERAPEUTICS, INC.** [US/US]; Suite 400, 501 Elliott
Avenue West, Seattle, WA 98119 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **BHATT, Rama**
[US/US]; 1810 NE 175th Street, Shoreline, WA 98155
(US). **GONG, Baoqing** [US/US]; 2324 N 178th Street,
Shoreline, WA 98133 (US). **HONG, Feng** [CN/US];
#301, 12316 - 32nd Avenue NE, Seattle, WA 98125 (US).
JENKINS, Scott, A. [US/US]; Apt. 1, 5339 Roosevelt
Way NE, Seattle, WA 98105 (US). **KLEIN, J., Peter**
[US/US]; 18822 Ridge Road SW, Vashon, WA 98070
(US). **KUMAR, Anil, M.** [IN/US]; 13701 - 113th Street
Court E, Puyallup, WA 98374 (US). **TULINSKY, John**
[US/US]; Apt. 6, 15 Aloha Street, Seattle, WA 98109
(US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: 6-PHENYL-N-PHENYL-(1,3,5)-TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH
LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE
TREATMENT OF CANCER



(57) Abstract: The invention relates to aryl triazines and uses
thereof, including to inhibit lysophosphatidic acid acyltransferase
 β (LPAAT- β) activity and/or proliferation of cells such as tumor
cells, where R^1 - R^5 are hydrogen or non-hydrogen substituents, and
Q is a heteroatom or heteroatom attached to one or more methylene
groups.

WO 03/037346 A1

ARYL TRIAZINES AS LPAAT- β INHIBITORS AND USES THEREOF

BACKGROUND OF THE INVENTION

Field of the Invention

The invention is in the field of organic and medicinal chemistry. In particular, the invention relates to aryl triazines and uses thereof, such as inhibiting the activity of lysophosphatidic acid acyltransferase β (LPAAT- β) activity and/or inhibiting the proliferation of a cell (e.g., tumor cell).

Description of the Related Art

Lysophosphatidic acid acyltransferase (LPAAT) catalyzes the acylation of lysophosphatidic acid (LPA) to phosphatidic acid. LPA is the simplest glycerophospholipid, consisting of a glycerol molecule, a phosphate group, and a fatty acyl chain. LPAAT adds a second fatty acyl chain to LPA, producing phosphatidic acid (PA). PA is the precursor molecule for certain phosphoglycerides, such as phosphatidylinositol, and diacylglycerols, which are necessary for the production of other phosphoglycerides, such as phosphatidylcholine, and for triacylglycerols, which are essential biological fuel molecules.

In addition to being a crucial precursor molecule in biosynthetic reactions, LPA has been added to the list of intercellular lipid messenger molecules. LPA interacts with G protein-coupled receptors, coupling to various independent effector pathways including inhibition of adenylate cyclase, stimulation of phospholipase C, activation of MAP kinases, and activation of the small GTP-binding proteins Ras and Rho. Moolenaar, *J. Biol. Chem.* 28:1294 (1995). The physiological effects of LPA have not been fully characterized as yet. However, one of the physiological effects that is known is that LPA promotes the growth and invasion of tumor cells. It has been shown that the addition of LPA to ovarian or breast cancer cell lines induces cell proliferation, increases intracellular calcium levels, and activates MAP kinase. Xu *et al.*, *Biochem. J.* 309:933 (1995). In addition, LPA has been shown to induce MM1 tumor cells to invade cultured mesothelial cell monolayers. Imamura *et al.*, *Biochem. Biophys. Res. Comm.* 193:497 (1993).

Like LPA, PA is also a messenger molecule. PA is a key messenger in a common signaling pathway activated by proinflammatory mediators such as

interleukin-1 β , tumor necrosis factor α , platelet activating factor, and lipid A. Bursten *et al.*, *Am. J. Physiol.* 262:C328 (1992); Bursten *et al.*, *J. Biol. Chem.* 255:20732 (1991); Kester, *J. Cell Physiol.* 156:317 (1993). PA has been implicated in mitogenesis of several cell lines [English, *Cell Signal* 8:341 (1996)].

5 PA level has been found to be increased in either ras or fps transformed cell lines compared to the parental Rat2 fibroblast cell line [Martin *et al.*, *Oncogene* 14:1571 (1997)]. Activation of Raf-1, an essential component of the MAPK signaling cascade, by extracellular signals is initiated by association with intracellular membranes. Recruitment of Raf-1 to membranes has been reported to be

10 mediated by direct association with phosphatidic acid [Rizzo *et al.*, *J. Biol. Chem.* 275:23911-8 (2000)]. Thus, LPAAT, as an enzyme that regulates PA content in cells, may play a role in cancer, and may also mediate inflammatory responses to various proinflammatory agents.

LPAAT exists in a LPAAT- α form and a LPAAT- β form. Northern blot

15 analysis shows that LPAAT- α is expressed in all human tissues tested with the highest expression level found in skeletal muscle (West *et al.*, *DNA Cell Biol.* 16:691 (1997)). The uniformity of LPAAT- α expression has also been found in additional tissues such as prostate, testis, ovary, small intestine, and colon (Stamps *et al.*, *Biochem. J.* 326:455 (1997)) as well as in mouse tissues (Kume *et al.*, *Biochem. Biophys. Res. Commun.* 237:663 (1997)). A 2 kb and a 1.3 kb

20 forms, possibly due to alternative utilization of polyadenylation signals at the 3'-UTR, have been found in murine LPAAT- α mRNA (Kume *et al.*, *Biochem. Biophys. Res. Commun.* 237:663 (1997)), whereas only one major human LPAAT- α mRNA of 2 kb in size has been detected by Northern analysis. West *et al.*, *DNA Cell Biol.*

25 16:691 (1997); Stamps *et al.*, *Biochem. J.* 326:455 (1997).

In contrast, LPAAT- β demonstrates a distinct tissue distribution of mRNA expression. West *et al.*, *DNA Cell Biol.* 16:691 (1997). LPAAT- β is most highly expressed in liver and heart tissues. LPAAT- β is also expressed at moderate levels in pancreas, lung, skeletal muscle, kidney, spleen, and bone

30 marrow; and at low levels in thymus, brain and placenta. This differential pattern of LPAAT- β expression has been confirmed independently (Eberhardt *et al.*, *J. Biol. Chem.* 272:20299 (1997)) with the only discrepancy being that high level, instead of moderate level, of LPAAT- β has been detected in pancreas, possibly due to slight lot variations in commercial RNA blots (Clontech, Palo Alto, CA). In

35 addition, moderate LPAAT- β expression has been found in prostate, testis, ovary, small intestine, and colon with the small intestine containing relatively higher


amounts. Eberhardt *et al.*, *J Biol Chem* 272:20299 (1997). Within various brain sections, high expression has been found in the subthalamic nucleus and spinal cord; and least in the cerebellum, caudate nucleus, corpus callosum, and hippocampus. LPAAT- β can also be detected in myeloid cell lines THP-1, HL-60, and U937 with the mRNA levels remaining the same with or without phorbol-ester treatment. The size difference between human LPAAT- α and LPAAT- β mRNA is consistent with the sequence data, in which LPAAT- α has a longer 3'-UTR. The differential tissue expression pattern LPAAT- α and LPAAT- β mRNA would suggest these two genes are regulated differently and are likely to have independent functions. Therefore, a desirable feature in compounds that inhibit LPAAT activity is that they are specific in inhibiting one isoform of the enzyme over the other (*i.e.*, LPAAT- β over LPAAT- α).

LPAAT- β mRNA has been found to be elevated in tumor tissues (*e.g.*, uterus, fallopian tube, and ovary), as compared to its expression in the corresponding normal tissues. However, no significant difference was found in LPAAT- α mRNA level between the various tumor tissues and the normal adjacent tissues. In two of the tumor tissues (fallopian tube and ovary) where LPAAT- α mRNA was elevated, PAP2- α mRNA expression was found to be suppressed, as it was also in tumors of the colon, rectum, and breast. Thus, LPAAT- β (rather than LPAAT- α) appears to be a relevant target for inhibition.

There is a need in the art for improved compositions and methods. The present invention fills this need, and further provides other related advantages.

BRIEF SUMMARY OF THE INVENTION

Briefly stated, the present invention provides a variety of compounds and uses thereof. More specifically, the compounds of the present invention are triazines that possess aromatic substituents which are directly or indirectly attached to two carbons of the triazine ring. The compounds are generally of the formula:



where R^1 - R^5 are hydrogen or non-hydrogen substituents, and Q is a heteroatom or heteroatom attached to one or more methylene groups. In preferred embodiments
 5 of compounds of the present invention:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

R^1 is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;

10 R^2 is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;

R^3 is H, alkyl, alkoxy, CCl₃, C≡N, NH₂, or SR where R and R' independently are alkyl;

R^4 and R^5 are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or
 15 NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R^4 and R^5 are taken together with the benzene ring to form a heterocycle or R^4 and R^5 are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R^4 and R^5 are
 20 attached; and

with the proviso that R^1 and R^2 are not both Cl where R^3 is NH₂ and Q is N;

with the proviso that R^4 and R^5 are not both H;


with the proviso that R^4 is not OCH₃ or t-butyl where R^1 is Cl, R^2 is H,
 25 R^3 is H, R^5 is NH and Q is NH;

with the proviso that where one of R^4 or R^5 is H, the other is not CH₃, OCH₃, Cl, Br or NO₂ where R^1 is OH or OCH₃, R^2 is Cl, R^3 is NH₂ and Q is NH;

with the proviso that R^4 and R^5 are not joined together to form naphthalene with the benzene ring to which R^4 and R^5 are attached where R^1 is
 30 OCH₃ or CH₂OH, R^2 is Cl, R^3 is NH₂ and Q is NH.

A compound or salt thereof as described above may be combined with a pharmaceutical carrier or diluent to form a pharmaceutical composition of the present invention.

A compound, salt thereof or pharmaceutical composition of the present invention, as well as other aryl triazines (or salts or pharmaceutical compositions thereof), may be used in one or more methods and medical devices of the present invention. In one method, the activity of LPAAT- β may be reduced by the step comprising contacting LPAAT- β with a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to reduce LPAAT- β activity, wherein the compound has the formula:



wherein:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

R¹ is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;

R² is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;


R³ is H, alkyl, alkoxy, Cl, CCl₃, C≡N, NH₂, NHR, NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N;

R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R⁴ and R⁵ are taken together with the benzene ring to form a heterocycle or R⁴ and R⁵ are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached; and

with the proviso that R¹ and R² are not both Cl where R³ is NH₂ and Q is N.

In another method, the proliferation of a cell in which the activity of LPAAT- β is required for the proliferation of the cell may be inhibited by the step comprising contacting the cell with a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to

5 inhibit the proliferation of the cell, wherein the compound has the formula:



wherein:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

10 R¹ is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;

R² is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;

R³ is H, alkyl, alkoxy, Cl, CCl₃, C≡N, NH₂, NHR, NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with

15 the N;

R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring


20 with the N, or R⁴ and R⁵ are taken together with the benzene ring to form a heterocycle or R⁴ and R⁵ are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached; and

with the proviso that R¹ and R² are not both Cl where R³ is NH₂ and

25 Q is N.

In a further method, the treatment of a cancer in which LPAAT- β activity is associated may be effected by the step comprising administering to an animal in need, a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to treat the

30 cancer, wherein the compound has the formula:



wherein:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

5 R¹ is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;


R² is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;

10 R³ is H, alkyl, alkoxy, Cl, CCl₃, C≡N, NH₂, NHR, NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N;

R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R⁴ and R⁵ are taken together with the benzene ring to form a heterocycle or R⁴ and R⁵ are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached; and

20 with the proviso that R¹ and R² are not both Cl where R³ is NH₂ and Q is N.

Also provided is a coated medical device for inhibiting the proliferation of a cell in which the activity of LPAAT-β is required for the proliferation of the cell comprising a medical device coated with a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to inhibit the proliferation of the cell, wherein the compound has the formula:



wherein:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

5 R¹ is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;

R² is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;

10 R³ is H, alkyl, alkoxy, Cl, CCl₃, C≡N, NH₂, NHR, NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N;

R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring
15 with the N, or R⁴ and R⁵ are taken together with the benzene ring to form a heterocycle or R⁴ and R⁵ are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached; and

20 with the proviso that R¹ and R² are not both Cl where R³ is NH₂ and Q is N.

These and other aspects of the present invention will become evident upon reference to the following detailed description.

DETAILED DESCRIPTION OF THE INVENTION

25 Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be used hereinafter.

In the present description, the term "alkyl" refers to straight- or branched-chain hydrocarbons having from 1 to 10 carbon atoms and more preferably 1 to 8 carbon atoms which include, by way of example, methyl, ethyl, *n*-

propyl, *i*-propyl, *n*-butyl, *t*-butyl and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more independently selected from alkyl, cycloalkyl, heteroalicyclic, aryl, heteroaryl, haloalkyl, halo, hydroxy, alkoxy, mercapto, cyano, sulfonamidyl, aminosulfonyl, acyl, acyloxy, and substituted amino.

“Alkenyl” includes monovalent hydrocarbon radicals having straight, cyclic, or branched moieties, and combinations thereof which comprise at least one carbon-carbon double bond. The alkenyl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more independently selected from alkyl, acyl, cycloalkyl, heteroalicyclic, aryl, haloalkyl, alkoxy and substituted amino.

“Alkoxy” refers to the group “-O-alkyl” which includes, by way of example, methoxy, ethoxy, *n*-propoxy, *i*-propoxy, *n*-butoxy, *t*-butoxy and the like. It further refers to the group “-O-alkyl-W-alkyl” where W is O or N; for example, -O-(CH₂)_n-W-(CH₂)_m where n and m are independently 1-10.

“Substituted amino” denotes the group -NRR, wherein each R group is independently selected from hydrogen, acyl, alkyl, cycloalkyl, aryl, or the R groups can be joined together with the nitrogen to form a heterocyclic ring (e.g., piperidine, piperazine, or a morpholine ring).

“Aryl” refers to an unsaturated aromatic carbocyclic group of 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). The aryl group may be unsubstituted or substituted; in the latter case, the substituent or substituents preferably are selected independently from alkyl, aryl, haloalkyl, halo, hydroxy, alkoxy, mercapto, cyano, sulfonamidyl, aminosulfonyl, acyl, acyloxy, nitro, and substituted amino.

“Heteroaryl” is a monocyclic or fused ring (*i.e.*, rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms selected preferably from nitrogen, oxygen and sulfur and, in addition, having a completely conjugated π -electron system. Exemplary heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, purine and carbazole. The heteroaryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more independently selected from alkyl, aryl, haloalkyl, halo, hydroxy, alkoxy, mercapto, cyano, sulfonamidyl, aminosulfonyl, acyl, acyloxy, nitro and substituted amino.

"Cycloalkyl" encompasses cyclic alkyl groups that contain between 3 and 8 carbon atoms and have a single cyclic ring, illustrated by cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl. The cycloalkyl ring may be substituted or unsubstituted.

- 5 Again, a substituted cycloalkyl ring carries one or more substituent groups, independently selected preferably from alkyl, aryl, haloalkyl, halo, hydroxy, alkoxy, mercapto, cyano, sulfonamidyl, aminosulfonyl, acyl, acyloxy, vitro, and substituted amino.

- 10 "Heteroalicyclic" refers to a monocyclic or fused ring group having in the ring(s) one or more atoms selected preferably from nitrogen, oxygen and sulfur. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated π -electron system. The heteroalicyclic ring may be substituted or unsubstituted. When substituted, the substituted group(s) preferably are selected independently from alkyl, aryl, haloalkyl, halo, hydroxy, 15 alkoxy, mercapto, cyano, sulfonamidyl, aminosulfonyl, acyl, acyloxy, vitro, and substituted amino.


"Halogen" or "halo" refers to fluoro, chloro, bromo, iodo.

- 20 "Acyl" group refers to the C(O)-R'' group, where R'' is selected preferably from hydrogen, hydroxy, alkyl, haloalkyl, cycloalkyl, aryl optionally substituted with one or more alkyl, haloalkyl, alkoxy, halo and substituted amino groups, heteroaryl (bonded through a ring carbon) optionally substituted with one or more alkyl, haloalkyl, alkoxy, halo and substituted amino groups and heteroalicyclic (bonded through a ring carbon) optionally substituted with one or more alkyl, haloalkyl, alkoxy, halo and substituted amino groups. Acyl groups 25 include aldehydes, ketones, acids, acid halides, esters and amides. Preferred acyl groups are carboxy groups, e.g., acids and esters. Esters include amino acid ester derivatives. The acyl group may be attached to a compound's backbone at either end of the acyl group, i.e., via the C or the R''.

- 30 The phrase "physiologically acceptable salt" refers to those salts that retain the biological effectiveness and properties of the particular compound. Physiologically acceptable salts are often useful because they may have improved stability and/or solubility in pharmaceutical compositions over the free base form of the compound. A physiologically acceptable salt may be obtained by reaction of a free base with an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric 35 acid, phosphoric acid, sulfuric acid, and perchloric acid and the like, or with an organic acid such as acetic acid, oxalic acid, malic acid, maleic acid,

methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid, and the like. A physiologically acceptable salt may also be obtained by reaction of a free acid with a base such as sodium, potassium or lithium hydroxide, bicarbonate or carbonate, and the like.

As noted above, the present invention provides aryl triazines, physiologically acceptable salts thereof and uses thereof. The triazines possess aromatic substituents that are directly or indirectly attached to two carbons of the aryl triazine ring. The compounds are generally of the formula:



where R^1 - R^5 are hydrogen or non-hydrogen substituents, and Q is a heteroatom or heteroatom attached to one or more methylene groups.

Preferred embodiments of a compound of the present invention, or a compound only for the methods and medical devices of the present invention where the compound was previously known, include the following selections for the general formula above. Preferred embodiments include where Q is a heteroatom (preferably N, O or S) and may be attached to one or more methylene groups to provide additional spacing between the triazine ring and the phenyl ring possessing R^4 and R^5 . Where there are one or more methylene groups, the heteroatom may be oriented such that it is attached directly to the triazine ring or attached directly to the phenyl ring possessing R^4 and R^5 . For example, Q may be $N-(CH_2)_n$, $(CH_2)_n-N$, $O-(CH_2)_n$, $(CH_2)_n-O$, $S-(CH_2)_n$ or $(CH_2)_n-S$, where n is typically 1-10. Particularly preferred is where Q is NH.

Preferred embodiments include where R^1 is H, OH, alkyl, alkoxy, halogen (preferably Cl, F or Br), CR_3 , NH_2 , NHR or NRR' . R_3 of CR_3 is (halo)₃, preferably Cl_3 , F_3 or Br_3 . R and R' of NHR and NRR' are independently alkyl. The term "independently," as used throughout, refers to independent selection of a group, but does not exclude the possibility that two groups are identical. For

example, the alkyl group of R and R' of NRR' may be the same or different. Particularly preferred is where R¹ is alkyl, alkoxy or Cl.

Preferred embodiments include where R² is H, OH, alkyl, alkoxy, halogen (preferably Cl, F or Br), or CR₃. R₃ of CR₃ is (halo)₃, preferably Cl₃, F₃ or Br₃. Particularly preferred is where R² is Cl.

Preferred embodiments include where R³ is H, alkyl, alkoxy, halogen (preferably Cl), CR₃, C≡N, NH₂, NHR, NRR' or SR. R₃ of CR₃ is (halo)₃, preferably Cl₃. R of SR is alkyl. R and R' of NHR and NRR' are independently alkyl, or R and R' are joined together to form a ring with the N. Examples of such rings include piperidine, piperazine and morpholine. Particularly preferred is where R³ is alkyl or NH₂.

Preferred embodiments include where R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR, halogen (preferably Cl, F or Br), CR₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR, NH₂, NHR or NRR'. R of (CH₂)_n-OR is H or alkyl, and n is typically 1-10, with CH₂-OH and (CH₂)₂-OH preferred. R₃ of CR₃ is (halo)₃, preferably Cl₃, F₃ or Br₃. A preferred heterocycle is oxazol. A preferred acyl is phenone (so forms benzophenone when taken with the benzene ring to which it is attached) or ester, such as an amino acid ester derivative. R of SR is alkyl. R and R' of NHR and NRR' are independently alkyl, or R and R' are joined together to form a ring with the N. Examples of such rings include piperidine, piperazine and morpholine. Particularly preferred is where R⁴ or R⁵ is Cl, Br, (CH₂)₂-OH, N⁺(=O)O⁻ or C≡N. Also preferred is where R⁴ or R⁵ is a non-polar substituent, e.g., alkyl. Alternatively, R⁴ and R⁵ may be taken together with the benzene ring to form a heterocycle. A preferred heterocycle is indazolyl, benzotriazolyl, indolyl, benzothiazolyl, benzimidazolyl or benzodioxolyl. Particularly preferred is where R⁴ and R⁵ are taken together with the benzene ring to form indazole. Alternatively, R⁴ and R⁵ are independently alkyl or alkenyl, and are joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached. A preferred ring is where R⁴ and R⁵ are taken together with the benzene ring to form indane.

Particularly preferred compounds of the present invention, or for use in the methods or medical devices of the present invention, are one or more of those shown in Table 1 of Example 91 below, and physiologically acceptable salts thereof.

It may be advantageous for certain uses to enhance the solubility and/or bioavailability of one or more of the compounds. This may be

accomplished, for example, by the addition of one or more substituents to the compound. For example, the addition of hydrophilic groups, such as hydroxyl groups, may be advantageous. Other substituents for enhancing solubility and/or bioavailability include amino acids (e.g., polyglutamate or polylysine), di-peptides, polymers (e.g., PEG or POG), monocarboxylic acids (e.g., hemi-succinate), and esters. Any group that enhances solubility and/or bioavailability of a compound may be used, provided that the group does not significantly impair the relevant biological property of the compound.

It may be advantageous for certain uses to prepare a compound (or physiologically acceptable salt thereof) as a "prodrug." As used herein, the term "compound" encompasses a prodrug form of the parent compound. "Prodrug" herein refers to a chemical substance that is converted into the parent compound *in vivo*. Prodrugs often are useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent compound. An example of a prodrug would be a parent compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility. The ester is then metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water solubility is beneficial. Such a prodrug is generally inactive (or less active) until converted to the active form.

Pharmaceutical compositions of the compounds of the present invention and the physiologically acceptable salts thereof are preferred embodiments of this invention. Pharmaceutical compositions of the compounds and salts thereof of the present invention may be manufactured by processes well known in the art; e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers or diluents. Proper formulation is generally dependent upon the route of administration chosen. The aryl triazines of the present invention may be formulated such that the formulation comprises a single aryl triazine or a mixture of two or more aryl triazines described herein. Alternatively, one or more aryl triazines may be formulated with one or

more other agents which are active for a general or specific disease, disorder or condition.

For injection, the compounds of the invention may be formulated as sterile aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with physiologically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be made with the use of a solid carrier or diluent, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable carriers or diluents are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid

polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

5 For administration by inhalation, the compounds for use according to the embodiments of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoro-ethane, carbon dioxide or other suitable gas. In the case of a
10 pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be
15 presented in unit dosage form, *e.g.*, in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

20 Pharmaceutical compositions for parenteral administration include sterile aqueous solutions of the active compounds in water soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl
25 oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

30 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

35 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation (see, for example, U.S. Patent No.

5,702,717 for a biodegradable depot for the delivery of a drug). Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example
5 as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. The pharmaceutical compositions herein also may comprise suitable solid or gel phase carriers or diluents. Examples of such carriers or diluents include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose
10 derivatives, gelatin, and polymers such as polyethylene glycols.

The compounds may be provided as physiologically acceptable salts wherein the compound may form the negatively or the positively charged species. Examples of salts in which the compound forms the positively charged moiety include, without limitation, quaternary ammonium (defined elsewhere herein), salts
15 such as the hydrochloride, sulfate, carbonate, lactate, tartarate, maleate, succinate, etc. formed by the reaction of an amino group with the appropriate acid.

As noted above, LPAAT- β appears to play a role in various cellular pathways that have a connection to various diseases, disorders or conditions. The disclosure of the present invention shows unexpectedly that the aryl triazines set
20 forth above inhibit the activity of LPAAT- β . This surprising inhibition is also specific for LPAAT- β , as the compounds tested showed weak to no inhibitory activity for LPAAT- α . In particular, none of the compounds tested for LPAAT- α had an IC_{50} of less than 40 μ M. In one use of the compounds of the present invention as well as other aryl triazines (collectively "compounds of the present disclosure", excluding
25 any particular aryl triazines previously known and used for the same specific purpose), the activity of LPAAT- β is reduced. The method comprises contacting LPAAT- β with a compound or salt thereof or composition of the present disclosure in an amount effective to reduce the LPAAT- β activity. The LPAAT- β to be contacted may reside in a cell-free preparation or in intact cells, including cells
30 within an animal.

In the context of the present invention, the term "animal" refers to any animal, including humans and other primates, rodents (e.g., mice, rats, and guinea pigs), lagamorphs (e.g., rabbits), bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g., goats), porcines (e.g., swine), equines (e.g., horses), canines (e.g., dogs);
35 felines (e.g., cats), domestic fowl (e.g., chickens, turkeys, ducks, geese, other gallinaceous birds, etc), as well as feral or wild animals, including such animals as

ungulates (e.g., deer), bear, fish, lagamorphs, rodents, birds, etc. It is not intended that the term be limited to a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are encompassed by the term. A preferred animal within the present invention is a mammal, with humans particularly preferred.

In another use of the compounds of the present disclosure, the proliferation of a cell (in which the activity of LPAAT- β is required for the proliferation of the cell) is inhibited. The method comprises contacting the cell with a compound or salt thereof or composition of the present disclosure in an amount effective to inhibit the proliferation of the cell. The cell to be contacted may be *in vitro* or *in vivo* in an animal. An example of a cell whose proliferation it is desirable to inhibit is a tumor cell. However, there are other diseases, disorders and conditions with cell types other than tumor cells for which it may be desirable to inhibit proliferation of the cell. In the context of the present invention, the term "inhibiting" refers to both total inhibition and partial inhibition (*i.e.*, the inhibition need not be 100%).

In another use of the compounds of the present disclosure, a cancer (in which LPAAT activity is associated) is treated. Examples of cancer include prostate, breast, lung, ovarian, brain, cervical, colon or bladder cancer. The method comprises administering to an animal in need, a compound or salt thereof or composition of the present disclosure in an amount effective to treat the cancer. In the context of the present invention, the term "treating a cancer" refers to any of a variety of positive effects from the treatment, including preventing the spread of a tumor, arresting tumor growth at a primary site, eradicating the tumor, relieving a symptom associated with the cancer, or prolonging the survival time of the animal treated. For example, as used herein, treating a cancer may have the effect of (1) reducing the size of the tumor, (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis, (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth, (4) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with the cancer, and/or (5) prolonging the survival time of the recipient. In addition, treatment further includes preventing tumor occurrence or recurrence. The method may further comprise inclusion of one or more other agents for treating a cancer. Alternatively, the method may be used in conjunction with one or more other cancer therapies, such as radiation, surgery or other chemotherapy.

Suitable routes of administration may include, without limitation, oral, rectal, transmucosal or intestinal administration or intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal or intranasal injections.

5 Alternately, one may administer the compound or composition in a local rather than systemic manner, for example, via injection of the compound or composition directly into a solid tumor, often in a depot or sustained release formulation.

10 Furthermore, one may administer the compound or composition in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

15 Compounds and compositions suitable for use in the methods of the present invention are compounds and compositions wherein the active ingredients are contained in an amount effective to achieve its intended purpose. Determination of an effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

20 For any compound or composition used in the methods of the invention, the effective amount or dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of LPAAT- β activity). Such information can be used to more accurately determine useful doses in humans.

25 Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the
30 therapeutic index and it can be expressed as the ratio between LD_{50} and ED_{50} . Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50}
35 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact

formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (see e.g., Fingl, et al., in "The Pharmacological Basis of Therapeutics," (1975), Chapter 1, pp. 1).

Dosage amount and interval may be adjusted individually to provide
5 plasma levels of the active moiety which are sufficient to maintain LPAAT- β inhibitory effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data; e.g., the concentration necessary to achieve 50-90% inhibition of LPAAT- β using the assays described herein. Dosages necessary to achieve the MEC will depend on individual
10 characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and
15 most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

The amount of compound or composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the
20 prescribing physician. An exemplary systemic daily dosage is about 5 to about 200 mg/kg of body weight. Normally, from about 10 to about 100 mg/kg of body weight of the compounds of the present invention, in one or more dosages per day, is effective to obtain the desired results. One of ordinary skill in the art can
25 determine the optimal dosages and concentrations of the compounds of the preferred embodiments of the present invention with only routine experimentation.

The compounds of the present invention when used are substantially pure and preferably sterile. The phrase "substantially pure" encompasses compounds created by chemical synthesis or compounds substantially free of
30 chemicals which may accompany the compounds in the natural state, as evidenced by thin layer chromatography (TLC) or high performance liquid chromatography (HPLC).

A compound or salt thereof of the present disclosure, or pharmaceutical composition of either, may be used to coat a medical device. A
35 variety of medical devices, such as a stent, may be coated. The medical device may be composed of a bioadsorbable and biodegradable material. Due to the

anti-proliferative properties of the compounds of the present disclosure, a stent or other medical device that is coated with such a compound or salt thereof or pharmaceutical composition of either may be used for inhibiting the proliferation of a cell. The coated medical devices of the present invention may be used in a variety of ways. A preferred use is to inhibit the proliferation of tumor cells.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES

10 Starting materials were purchased from the following sources:

Aldrich Chemical Company, St Louis, MO
Lancaster Synthesis, Windham, NH
Matrix Scientific, Columbia, SC
Trans World Chemicals, Rockville, MD

15 Avocado Research Chemicals, Heysham, Lancashire, UK
TCI America, Portland, OR
Bachem Bioscience Inc, King of Prussia, PA
Advanced ChemTech, Louisville, KY

Synthesis of Compounds Used in Certain Examples Below

20 2,4-Dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine

To a suspension of 5-chloro-2-methylbenzoic acid (10 g, 58.6 mmol) dichloromethane (100 ml), cooled in an ice bath, was added a solution of oxalyl chloride in dichloromethane (2 M, 33 ml, 66 mmol) followed by N,N-dimethylformamide (5 drops). After stirring for 2 hours, dimethylamine hydrochloride (9.5 g, 116 mmol) was added followed by a solution of trimethylamine (25 ml, 180 mmol) in dichloromethane (100 ml) slowly. After stirring for 3 hours, the mixture was concentrated under reduced pressure and partitioned between ethyl acetate (200 ml) and hydrochloric acid (1 M, 200 ml). The organic layer was concentrated under reduced pressure to afford 2-chloro-5,N,N-trimethyl benzamide (11.6 g, 100% yield).

30 A mixture of 2-chloro-5,N,N-trimethyl benzamide (7.5 g, 37.9 mmol) and phosphorus oxychloride (3.9 ml, 41.7 mmol) was heated at 100 °C for 15 minutes. After cooling to 30°C, dichloromethane (75 ml) and chlorocycloamidine

(6.4 g, 61.8 mmol), prepared according to the method described in *Zeitschrift für Anorganische und Allgemeine Chemie* 322:265-285 (1963), were added. After stirring for 20 hours, the mixture was treated with water (300 ml) and dichloromethane (150 ml). The organic layer was concentrated under reduced
5 pressure. The residue was purified by flash chromatography on silica gel eluting with hexane to provide 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine (3.0 g, 29% yield) as a white powder. ¹H NMR (CDCl₃) 8.26 (m, 1H), 7.50 (m, 1H), 7.32 (s, 1H), 2.70 (s, 3H).

Alternatively, to a mixture of magnesium (1.46 g, 60.0 mmol) and
10 tetrahydrofuran (100 ml) was added a small crystal of iodine followed by 4-chloro-2-iodo-toluene (12.62 g, 50 mmol). The mixture was heated under gentle reflux in an argon atmosphere for 6 hours and then cooled to -78°C. A solution of cyanuric chloride (7.84 g, 42.5 mmol) in tetrahydrofuran (45 ml) was added over 25 minutes. After stirring at -78°C for 1 hour, the mixture was slowly warmed to room
15 temperature and stirred for 16 hours. The reaction mixture, cooled in an ice bath, was quenched by slow addition of hydrochloric acid (1 M, 15 ml). The mixture was diluted with water (150 ml) and extracted with dichloromethane (3x 125 ml). The combined extracts was washed with water (150 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash
20 chromatography on silica gel eluting with ethyl acetate-hexane (7:93) to provide 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine (10.2 g, 87% yield) as a white powder.

2,4-Dichloro-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazine

To a mixture of 5-chlorosalicylic acid (20.0 g, 116 mmol) and
25 potassium carbonate (48.4 g, 350 mmol) in acetonitrile (300 ml) was added iodoethane (24.0 ml, 299 mmol). The mixture was heated under reflux for 24 hours. After cooling to room temperature, the mixture was filtered through a pad of celite under suction and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (200 ml). The solution was washed
30 with water (100 ml), washed with aqueous sodium hydroxide solution (1 M, 2x 100 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was dissolved in ethanol (200 ml) and a solution of sodium hydroxide (10.7 g, 268 mmol) in water (50 ml) was added. The mixture was heated under reflux for 90 minutes. After cooling to room temperature, the mixture was concentrated
35 under reduced pressure. The residue was dissolved in water (100 ml) and the

solution was washed with diethyl ether (2x 50 ml). The solution was adjusted to pH 2 by the careful addition of concentrated hydrochloric acid. After 60 minutes, the solid was filtered and dried under reduced pressure to provide 5-chloro-2-ethoxybenzoic acid (20.4 g, 90% yield).

- 5 Using the method described for the synthesis of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine, 5-chloro-2-ethoxybenzoic acid afforded 2,4-dichloro-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazine (9.5 g, 31% yield). ¹H NMR (DMSO-d₆) 7.62-7.86 (m, 2H), 7.20-7.31 (m, 1H), 4.20 (m, 2H), 1.37 (m, 3H).

2,4-Dichloro-6-(2,5-dichloro-phenyl)-[1,3,5]triazine

- 10 Using the method described for the synthesis of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine, 2,5-dichlorobenzoic acid afforded 2,4-dichloro-6-(2,5-dichloro-phenyl)-[1,3,5]triazine (2.2 g, 14% yield). ¹H NMR (DMSO-d₆) 8.10 (s, 1H), 7.50 (m, 2H).

- Alternatively, to a solution of 2,5-dichloro-iodobenzene (3.1 g, 11.4 mmol), hexamethylphosphoramide (6.6 ml) and tetrahydrofuran (20 ml), cooled to -78°C, was added a solution of tert-butyl lithium in pentane (1.7 M, 8.7 ml, 14.8 mmol) over 20 minutes. After stirring at -78°C for 3 hours, a solution of cyanuric chloride (3.14 g, 17.1 mmol) in tetrahydrofuran (15 ml) was added over 15 minutes. After stirring at -78°C for 1 hour, the mixture was warmed to -20°C over 15 minutes. After stirring at -20°C for 1 hour, the mixture was warmed to -20°C over 30 minutes. The reaction was quenched by slow addition of hydrochloric acid (1 M, 20 ml). The mixture was diluted with water (50 ml) and extracted with dichloromethane (3x 40 ml). The combined extracts were washed with water (2x 50 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane-hexane (3:5) to provide 2,4-dichloro-6-(2,5-dichloro-phenyl)-[1,3,5]triazine (1.98 g, 59% yield).

EXAMPLE 1

6-(5-CHLORO-2-METHOXYPHENYL)-N-(4-CHLOROPHENYL)- [1,3,5]TRIAZINE-2,4-DIAMINE

- 30 To a suspension of 1-(4-chlorophenyl)biguanidine hydrochloride (971 mg, 3.9 mmol) in 2 M aqueous sodium hydroxide solution (9 ml) was added a solution of 2-methoxy-5-chlorobenzoyl chloride (1.41 g, 3.9 mmol) in acetone (9 ml). After stirring for 48 hours, the acetone was removed by evaporating under vacuum. The remaining mixture was acidified to pH 2 by the addition of 1 M

hydrochloric acid. The solid was filtered and purified by flash chromatography on silica gel eluting with 2% methanol-dichloromethane to provide the title compound (181 mg, 13% yield). ¹H NMR (DMSO-d₆) δ 9.72 (br s, 1 H), 7.83 (d, J = 11 Hz, 2 H), 7.41-7.58 (m, 2 H), 7.10-7.35 (m, 5 H), 3.77 (s, 3 H).

5

EXAMPLE 2

6-(5-CHLORO-2-METHOXYPHENYL)-N-PHENYL-
[1,3,5]TRIAZINE-2,4-DIAMINE

To a mixture of 1-phenylbiguanidine hydrochloride (231 mg, 1.08 mmol) and methyl 2-methoxy-5-chlorobenzoate (0.16 ml, 1.0 mmol) in absolute ethanol (5 ml) was added 21 weight % sodium ethoxide in ethanol (1.1 ml, 2.95 mmol). The mixture was heated at reflux for 21 hours. Upon cooling to room temperature the mixture was concentrated under vacuum. The residual solid was suspended in water (5 ml), filtered and purified by flash chromatography on silica gel eluting with 2% methanol-dichloromethane to provide the title compound (90 mg, 27% yield). ¹H NMR (CDCl₃) δ 7.92 (br s, 1 H), 7.65 (br s, 1 H), 7.49-7.55 (m, 2 H), 7.23-7.35 (m, 3 H), 7.02-7.09 (m, 1 H), 6.84-6.88 (m, 1 H), 3.84 (s, 3 H).

15

EXAMPLE 3

6-(5-CHLORO-2-METHOXYPHENYL)-N-(4-NITROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-nitrophenyl)biguanidine hydrochloride with methyl 2-methoxy-5-chlorobenzoate using the method described in Example 2 provided the title compound (36 mg, 18% yield).

20

EXAMPLE 4

6-(2,5-DICHLOROPHENYL)-N-(4-CHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

25

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride with methyl 2,5-dichlorobenzoate using the method described in Example 2 provided the title compound (70 mg, 19% yield). ¹H NMR (DMSO-d₆) δ 9.84-9.90 (br, 1 H), 7.84 (d, 2H), 7.70 (d, 1H), 7.52-7.62 (m, 2H), 7.37-7.45 (br, 1H), 7.32 (d, 2H).

EXAMPLE 5

N-BENZO[1,3]DIOXOL-5-YL-6-(5-CHLORO-2-METHOXYPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of methyl 5-chloro-2-methoxybenzoate and 1-(3,4-
5 methylenedioxyphenyl)biguanidine hydrochloride using the method described in
Example 2 provided the title compound (105 mg, 28% yield). ¹H NMR (DMSO-d₆)
δ 9.45-9.60 (br, 1 H), 7.60-7.70 (br, 1 H), 7.47 (dd, 1 H), 7.14 (d, 1 H), 7.08 (m, 1 H),
6.82 (d, 1 H), 5.55 (s, 2 H), 3.85 (s, 3 H).

EXAMPLE 6

10 N-(4-CHLOROPHENYL)-6-(2-FLUORO-5-METHOXYPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of methyl 5-fluoro-2-methoxybenzoate and 1-(4-
chlorophenyl)biguanidine hydrochloride using the method described in Example 2
provided the title compound (62 mg, 18% yield). ¹H NMR (DMSO-d₆) δ 9.70-9.80
15 (br, 1 H), 7.97 (d, 2 H), 7.32 (d, 2 H), 7.09-7.4 (m, 5 H), 3.77

EXAMPLE 7

6-(5-CHLORO-2-ETHOXYPHENYL)-N-(4-CHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride with
20 ethyl 2-ethoxy-5-chlorobenzoate using the method described in Example 2
provided the title compound (102 mg, 15% yield). ¹H NMR (DMSO-d₆) δ 9.70 (br s,
1 H), 7.86 (d, J = 11 Hz, 2 H), 7.40-7.51 (m, 2 H), 7.08-7.35 (m, 5 H), 4.06 (q, J =
12 Hz, 2 H), 1.27 (t, J = 12 Hz, 3 H).

EXAMPLE 8

25 6-(5-CHLORO-2-METHOXYPHENYL)-N-(3, 4-DICHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(3, 4-dichlorophenyl)biguanidine hydrochloride with
methyl 2-methoxy-5-chlorobenzoate using the method described in Example 2
provided the title compound (106 mg, 8% yield). ¹H NMR (DMSO-d₆) δ 9.90 (br s,
30 1 H), 8.30 (br s, 1 H), 7.73 (d, J = 15 Hz, 1 H), 7.20-7.64 (m, 5 H), 7.15 (d, J = 14
Hz, 1 H), 3.81 (s, 3 H).

EXAMPLE 9

6-(5-CHLORO-2-METHYLPHENYL)-N-(4-CHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride with
5 methyl 2-methyl-5-chlorobenzoate using the method described in Example 2
provided the title compound (46 mg, 6% yield). ¹H NMR (DMSO-d₆) δ 9.71 (br s, 1
H), 7.65-7.87 (m, 3 H), 7.18-7.44 (m, 6 H), 2.50 (s, 3 H).

EXAMPLE 10

10 N-2-(4-BROMOPHENYL)-6-(5-CHLORO-2-METHOXYPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-bromophenyl)biguanidine hydrochloride (4.99 g,
17.0 mmol) with methyl 5-chloro-2-methoxybenzoate (3.15 g, 15.7 mmol) using the
method described in Example 2 provided the title compound (1.47 g, 23% yield).
¹H NMR (DMSO-d₆) δ 9.72 (br s, 1 H), 7.82 (d, J = 10 Hz, 2 H), 7.37-7.57 (m, 3 H),
15 7.11-7.30 (m, 3 H), 3.78 (s, 3 H).

EXAMPLE 11

N-2-(4-BROMOPHENYL)-6-(5-CHLORO-2-METHYLPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-bromophenyl)biguanidine hydrochloride (464
20 mg, 1.59 mmol) with methyl 5-chloro-2-methylbenzoate (239 mg, 1.73 mmol) using
the method described in Example 2 provided the title compound (46 mg, 8% yield).
¹H NMR (DMSO-d₆) δ 9.72 (br s, 1 H), 7.75-7.83 (m, 2 H), 7.38-7.48 (m, 3 H), 7.16-
7.33 (m, 2 H), 2.51 (s, 3 H).

EXAMPLE 12

25 N-2-(4-BROMOPHENYL)-6-(2,5-DICHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-bromophenyl)biguanidine hydrochloride (317
mg, 1.08 mmol) with methyl 2,5-dichlorobenzoate (205 mg, 1.0 mmol) using the
method described in Example 2 provided the title compound (53 mg, 13% yield).
30 ¹H NMR (DMSO-d₆) δ 9.90 (br s, 1 H), 7.70-7.82 (m, 3 H), 7.55-7.60 (m, 2 H), 7.31-
7.48 (m, 5 H).

EXAMPLE 13

6-(5-CHLORO-2-METHYL-PHENYL)-N-(1H-INDAZOL-6-YL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(1H-indazol-6-yl)biguanidine hydrochloride (1.6 g, 6.3 mmol) with methyl 5-chloro-2-methyl benzoate (1.8 g, 9.5 mmol) using the method described in Example 2 provided the title compound (261 mg, 12% yield). ¹H NMR (DMSO-d₆) δ 12.85 (br s, 1 H), 9.71 (br s, 1 H), 8.06 (s, 1 H), 7.95 (s, 1 H), 7.78 (m, 1 H), 7.61-7.64 (m, 1 H), 7.41-7.44 (m, 2 H), 7.31-7.34 (m, 1 H), 7.23 (br s, 2 H), 2.54 (s, 3 H).

10

EXAMPLE 14

N-(4-CHLOROPHENYL)-6-(2,5-DIMETHYLPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride (268 mg, 1.08 mmol) with methyl 2,5-dimethylbenzoate (165 mg, 1.0 mmol) using the method described in Example 2 provided the title compound (44 mg, 13% yield). ¹H NMR (DMSO-d₆) δ 9.64 (br s, 1 H), 7.85 (d, 2 H, J = 10 Hz), 7.53 (s, 1 H), 7.31 (d, 2 H, J = 10 Hz), 7.13-7.22 (m, 4 H), 2.46 (s, 3 H), 2.30 (s, 3 H).

EXAMPLE 15

6-(5-CHLORO-2-METHOXYPHENYL)-N-(4-FLUOROPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-fluorophenyl)biguanidine hydrochloride (927 mg, 3.9 mmol) with methyl 5-chloro-2-methoxybenzoate (782 mg, 3.9 mmol) using the method described in Example 2 provided the title compound (100 mg, 7% yield). ¹H NMR (DMSO-d₆) δ 9.62 (br s, 1 H), 7.79-7.86 (m, 2 H), 7.44-7.56 (m, 1 H), 7.07-7.22 (m, 5 H), 6.88-6.93 (m, 1 H), 3.80 (s, 3 H).

25

EXAMPLE 16

N-(4-CHLOROPHENYL)-6-(3-CHLOROPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride (268 mg, 1.08 mmol) with methyl 3-chlorobenzoate (0.139 ml, 1.0 mmol) using the method described in Example 2 provided the title compound (81 mg, 24% yield). ¹H NMR (DMSO-d₆) δ 9.75 (br s, 1 H), 8.20-8.33 (m, 2 H), 7.87 (d, 2 H, J = 8 Hz), 7.52-7.67 (m, 2 H), 7.22-7.44 (m, 4 H).

30

EXAMPLE 17

N-(4-CHLOROPHENYL)-6-(2,5-DIMETHOXYPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride (268 mg, 1.08 mmol) with methyl 2,5-dimethoxybenzoate (195 mg, 1.0 mmol) using the method described in Example 2 provided the title compound (61 mg, 17% yield).
 5 ¹H NMR (DMSO-d₆) δ 9.70 (br s, 1 H), 7.88 (d, 2 H, *J* = 9 Hz), 7.31 (d, 2 H, *J* = 9 Hz), 6.96-7.27 (m, 5 H), 3.75 (br s, 6 H).

EXAMPLE 18

10 POLY-(L-GLUTAMIC ACID) CONJUGATE OF 4-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]-TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL

A mixture of the title compound of Example 41 (3.8 g, 11.1 mmol), poly-(L-glutamic acid) (21.5 g), pyridine (4.8 ml), *N,N*-dimethylaminopyridine (0.470 g, 3.85 mmol), *N,N*-dimethylformamide (300 ml), and *N,N*-diisopropylcarbodiimide (1.8 g, 14.2 mmol) was stirred for 6 hours. A 10% aqueous sodium chloride
 15 solution (800 ml) was added and the mixture was adjusted to pH 2.5 by the addition of 1 M hydrochloric acid. After stirring for 30 minutes, the solid was filtered, washed with water (5x 200 ml), dried by lyophilization, washed with acetonitrile (4x 200 ml), and dried under reduced pressure to provide the title compound (19.6 g, 77% mass balance). ¹H NMR (TFA-d): 7.44-7.77 (m, 7 H),
 20 5.27-5.35 (m, 2H), 4.65-4.95 (br s, 1H, poly-(L-glutamic acid) backbone), 2.52-2.75 (br s, 2H, poly-(L-glutamic acid) backbone), 2.24-2.42 (br s, 1H, poly-(L-glutamic acid) backbone) 2.02-2.09(br s, 1H, poly-(L-glutamic acid) backbone). Ratios of integrals in the ¹H NMR spectrum indicated 20% by weight of the title compound of Example 41 in this sample.

25

EXAMPLE 19

 N-BENZO[1.3]DIOXOL-5-YL-6-(5-CHLORO-2-METHYL-PHENYL)-
 [1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(3,4-methylenedioxy-phenyl)-biguanidine hydrochloride and methyl 5-chloro-2-methyl-benzoate using the method described
 30 in Example 2 provided the title compound (5% yield). ¹H NMR (DMSO-d₆) 9.44 (br s, 1H), 8.72 (m, 1H), 7.54 (s, 1H), 7.40 (m, 1H), 7.30 (m, 1H), 7.04-7.15 (m, 3H), 6.82 (m, 1H), 5.92 (s, 2H), 2.50 (s, 3H).

EXAMPLE 20

(4-BROMO-PHENYL)-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YL]-AMINE

A mixture of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine
5 (2.5 g, 9.1 mmol), 4-bromoaniline (1.6 g, 9.3 mmol), tetrahydrofuran (60 ml), and
diisopropylethylamine (1.6 ml, 9.2 mmol) was stirred for 1 hour. The solution was
treated with dichloromethane (200 ml), washed with saturated aqueous sodium
chloride solution (50 ml), and concentrated under reduced pressure. The residual
10 solid was treated with hydrochloric acid (1 M, 25 ml) and stirred vigorously for 30
minutes. Filtration and drying under reduced pressure provided the title compound
(3.2 g, 86% yield). ¹H NMR (DMSO-d₆) 10.75-10.80 (m, 1H), 7.85-7.92 (m, 1H),
7.50-7.65 (m, 4H), 7.40 (m, 1H), 2.58 (s, 3H).

EXAMPLE 21

(4-BROMO-PHENYL)-[4-(5-CHLORO-2-METHYL-PHENYL)-6-METHOXY-
15 [1,3,5]TRIAZIN-2-YL]-AMINE

To a solution of the title compound of Example 20 (100 mg, 0.25
mmol) in methanol (5 ml) was added a solution of sodium methoxide in methanol
(25-30%, 0.5 ml). After stirring for 72 hours, the mixture was concentrated under
reduced pressure. The residue was stirred with water (20 ml). The solid was
20 collected by filtration, washed with hexane (5 ml), and dried under reduced
pressure to provide the title compound (60 mg, 59% yield). ¹H NMR (DMSO-d₆)
10.40 (s, 1H), 7.90 (s, 1H), 7.75 (m, 2H), 7.48-7.55 (m, 3H), 7.38 (m, 1H), 3.98 (s,
3H), 2.54 (s, 3H).

EXAMPLE 22

25 [4-(5-CHLORO-2-METHYL-PHENYL)-6-METHYL-[1,3,5]TRIAZIN-2-YL]-
(1H-INDAZOL-6-YL)-AMINE

A mixture of the title compound of Example 26 (200 mg, 0.54 mmol),
methyl magnesium bromide (3 M in diethyl ether, 1.8 ml, 5.4 mmol), and
tetrahydrofuran (4 ml) was stirred at 40°C for 24 hours. After cooling in an ice
30 bath, the reaction was quenched by dropwise addition of water (2 ml). The mixture
was treated with hydrochloric acid (1 M, 25 ml), stirred for 5 minutes, and extracted
with dichloromethane (50 ml). The organic extract was dried over sodium sulfate

and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting ethyl acetate-hexane (1:1) followed by recrystallization (ethyl acetate) to provide the title compound (40 mg, 21% yield).
5 ¹H NMR (DMSO-d₆) 12.95 (s, 1H) 10.41 (br s, 1H), 8.15 (s, 1H), 7.87-7.98 (m, 1H), 7.67-7.70 (m, 1H), 7.49-7.51 (m, 1H), 7.34-7.40 (m, 3H), 2.56 (s, 3H), 2.53 (s, 3H).

EXAMPLE 23

(4-BROMO-PHENYL)-[4-(5-CHLORO-2-METHYL-PHENYL)-6-METHYL-
[1,3,5]TRIAZIN-2-YL-AMINE

The reaction of the title compound of Example 20 (200 mg, 0.49
10 mmol) with methyl magnesium bromide (3 M in diethyl ether, 1 ml, 3 mmol) in tetrahydrofuran (4 ml) using the method described in Example 22 provided the title compound (62 mg, 32% yield). ¹H NMR (DMSO-d₆) 10.37 (s, 1H), 7.85 (s, 1H), 7.71 (m, 2H), 7.47-7.54 (m, 3H), 7.38 (m, 1H), 2.53 (s, 3H), 2.50 (s, 3H).

EXAMPLE 24

15 (4-BROMO-PHENYL)-[4-(5-CHLORO-2-METHYL-PHENYL)-6-ETHYL-
[1,3,5]TRIAZIN-2-YL-AMINE

The reaction of the title compound of Example 20 (200 mg, 0.49
mmol) with ethyl magnesium bromide (1 M in diethyl ether, 7.5 ml, 7.5 mmol) in tetrahydrofuran (2 ml) using the method described in Example 22 provided the title
20 compound (44 mg, 22% yield). ¹H NMR (CDCl₃) 7.80 (m, 1H), 7.48 (d, J = 8.8 Hz, 2H), 7.38 (d, J = 8.8 Hz, 2H), 7.09-7.12 (m, 2H), 2.79 (q, J = 7.4 Hz, 4H), 1.13 (t, J = 7.0 Hz, 3H).

EXAMPLE 25

25 6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-CHLORO-PHENYL)-N-METHYL-
[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of 4-chloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-yl-amine (106 mg, 0.42 mmol), (4-chloro-phenyl)-methyl-amine (0.15 ml, 1.25 mmol), tetrahydrofuran (5 ml), and diisopropylethylamine (0.75 ml, 4.2 mmol) was heated at 40°C for 72 hours. The mixture was concentrated under reduced pressure and
30 the residue was dissolved in dichloromethane (25 ml). The solution was washed with hydrochloric acid (1 M, 25 ml) and concentrated under reduced pressure. The

residue was purified by flash chromatography on silica gel eluting with 2% methanol-dichloromethane followed by 5% methanol-dichloromethane. Recrystallization (ethyl acetate-hexane) provided the title compound (33 mg, 22% yield). ¹H NMR (DMSO-d₆) 7.78 (s, 1H), 7.37-7.46 (m, 4H), 7.26 (d, J = 8.4 Hz, 5 1H), 7.10 (br s, 2H), 3.43 (s, 3H), 2.37 (s, 3H).

EXAMPLE 26

[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-2-YL]-
(1H-INDAZOL-6-YL)-AMINE

A mixture of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine
10 (1 g, 3.6 mmol), 6-aminoindazole (0.5 g, 3.7 mmol), tetrahydrofuran (10 ml), and diisopropylethylamine (0.65 ml, 3.7 mmol) was stirred for 1 hour. After concentrating under reduced pressure, the residue was treated with water (25 ml) and stirred for 10 minutes. The solid was filtered, treated with hydrochloric acid (1 M, 10 ml), stirred vigorously for 10 minutes, and filtered. The solid was purified by
15 flash chromatography on silica eluting with 5% methanol-dichloromethane to yield the title compound (600 mg, 45% yield). ¹H NMR (DMSO-d₆) 13.04 (br s, 1H), 10.90-10.97 (m, 1H), 8.12 (s, 1H), 8.02 (s, 1H), 7.71 (m, 2H), 7.53 (m, 1H), 7.41 (m, 1H), 7.34 (m, 1H), 2.50-2.54 (m, 3H).

EXAMPLE 27

20 [2-AMINIMETHYL-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-4-YL]-
(4-BROMO-PHENYL)-AMINE

To a suspension of lithium aluminum hydride (7 mg, 0.17 mmol) in anhydrous tetrahydrofuran (1.5 ml), cooled to -78°C, was added a solution of 6-(2,5-dichloro-2-methyl-phenyl)-(4-bromo-phenyl)-[1,3,5]-triazine-2-carbonitrile (35
25 mg, 0.09 mmol) in tetrahydrofuran (0.5 ml) dropwise during 10 minutes. After stirring at -78°C for 2 hours, the reaction was quenched by dropwise addition of water (5 ml). The mixture was extracted with ethyl acetate (3x 10 ml). The combined extracts were washed with water (25 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative
30 thin layer chromatography eluting with 7% methanol-dichloromethane to provide the title compound (16 mg, 48% yield) as a yellow powder. ¹H NMR (CD₃OD) δ 7.85 (d, J = 8.8 Hz, 2H), 7.31-7.75 (m, 5H), 3.60 (s, 2H).

EXAMPLE 28

6-(5-CHLORO-2-METHYL-PHENYL)-(4-BROMO-PHENYL)-[1,3,5]-TRIAZINE-2-CARBONITRILE

A solution of [6-(5-chloro-2-methyl-phenyl)-2-chloro-3-yl-[1,3,5]triazin-4-yl]-(4-bromo-phenyl)-amine (411 mg, 1.0 mmol), potassium cyanide (78 mg, 1.2 mmol), and anhydrous dimethylsulfoxide (20 ml) was heated at 60°C for 4 hours. After cooling to room temperature, the solution was treated with water (50 ml) and extracted with dichloromethane (2x 25 ml). The combined extracts were dried over sodium sulfate, and concentrating under reduced pressure. The residue was crystallized (ethyl acetate) to give the title compound (361 mg, 91% yield) as a yellow powder. ¹H NMR (CD₃OD) δ 7.91 (d, J = 8.9 Hz, 2H), 7.15-7.60 (m, 5H), 2.60 (s, 3H).

EXAMPLE 29

(4-BROMO-PHENYL)-[4-(5-CHLORO-2-METHYL-PHENYL)-6-METHYLSULFANYL-[1,3,5]TRIAZIN-2-YL]-AMINE

A mixture of the title compound of Example 20 (234 mg, 0.57 mmol), sodium thiomethoxide (50 mg, 0.71 mmol), and tetrahydrofuran (5 ml) was stirred for 24 hours. After concentrating under reduced pressure, the residue was dissolved in dichloromethane (25 ml). The solution was washed with water (25 ml) and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane-hexane (1:1) to provide the title compound (137 mg, 57% yield). ¹H NMR (DMSO-d₆) 10.42 (s, 1H), 7.88 (s, 1H), 7.70 (s, 2H), 7.45-7.55 (m, 3H), 7.38 (m, 1H), 2.55 (s, 3H), 2.50 (s, 3H).

EXAMPLE 30

[6-(5-CHLORO-2-METHYL-PHENYL)-2-CHLORO-3-YL-[1,3,5]-TRIAZIN-4-YL]-(4-NITRO-PHENYL)-AMINE

A mixture of [6-(5-chloro-2-methyl-phenyl)-2,4-dichloro-1,3,5]triazine (0.5 g, 1.82 mmol), 4-nitroaniline (277 mg, 2.0 mmol), anhydrous tetrahydrofuran (8 ml), and N,N-diisopropylethylamine (470 mg, 3.64 mmol) was stirred for 12 hours. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50 ml). The solution was washed with hydrochloric acid (1 M, 25 ml), washed with water (50 ml), dried over sodium

sulfate, and concentrated under reduced pressure to provide the title compound (605 mg, 88% yield) as a yellow powder. ^1H NMR ($\text{DMSO}-d_6$) δ 11.38 (br s, 1H), 8.31 (d, $J = 9.1$ Hz, 2H), 7.99 (d, $J = 9.1$ Hz, 2H), 7.92 (s, 1H), 7.38-7.56 (dd, $J = 2.3, 8.2$ Hz, 1H), 7.42 (d, $J = 8.2$ Hz, 1H), 2.51 (s, 3H).

5

EXAMPLE 31

[6-(5-CHLORO-2-METHYL-PHENYL)-2-PIPERIDIN-3-YL-[1,3,5]TRIAZIN-4-YL]-
(4-CHLORO-PHENYL)-AMINE

A solution of [6-(5-chloro-2-methyl-phenyl)-2-chloro-3-yl-[1,3,5]triazin-4-yl]-(4-chloro-phenyl)-amine (150 mg, 0.41 mmol), piperidine (70 mg, 0.82 mmol),
10 and ethylene glycol dimethyl ether (2 ml) was stirred at 80°C for 16 hours. After concentrating under reduced pressure, the solid residue was recrystallized (ethyl acetate-hexane, 1:4) to provide the title compound (151 mg, 89% yield) as white flakes. ^1H NMR ($\text{DMSO}-d_6$) δ 9.72 (br s, 1H), 7.85(s, 1H), 7.75 (d, $J = 8.8$ Hz, 2H), 7.47 (dd, $J = 2.4, 8.2$ Hz, 1H), 7.40-7.34 (m, 3H), 3.82 (br s, 4H), 2.52 (s, 3H),
15 1.57-1.66 (m, 6H).

EXAMPLE 32

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-CHLORO-PHENYL)-N,N-DIMETHY-
[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of [6-(5-Chloro-2-methyl-phenyl)-2-chloro-3-yl-
20 [1,3,5]triazin-4-yl]-(4-chloro-phenyl)-amine (150 mg, 0.41 mmol) and a saturated solution of dimethylamine in ethylene glycol dimethyl ether (2 ml) was stirred at 80°C for 16 hours. After concentrating under reduced pressure, the solid residue was crystallized (ethyl acetate-hexane, 1:4) to provide the title compound (134 mg, 87% yield) as a white powder. ^1H NMR ($\text{DMSO}-d_6$) δ 9.89 (br s, 1H), 7.87(d, $J = 2.2$ Hz, 1H), 7.81 (d, $J = 8.8$ Hz, 2H), 7.47 (dd, $J = 2.4, 8.2$ Hz, 1H), 7.36-7.39 (m, 3H), 3.25 (s, 6H), 2.52 (s, 3H).
25

EXAMPLE 33

[6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-4-YL]-(4-CHLORO-PHENYL)-AMINE

To a suspension of lithium aluminum hydride (31 mg, 0.82 mmol) in
30 anhydrous tetrahydrofuran (2 ml), cooled to -78°C was added a solution of [6-(5-Chloro-2-methyl-phenyl)-2-chloro-3-yl-[1,3,5]triazin-4-yl]-(4-chloro-phenyl)-amine

(150 mg, 0.41 mmol) in tetrahydrofuran (1 ml) dropwise over 10 minutes. The mixture was stirred at -78°C for 2 hours and at 0°C for an additional 6 hours. The reaction was quenched by dropwise addition of water (5 ml) and extracted with ethyl acetate (2x 15 ml). The combined extracts were washed with water (25 ml),
5 dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with hexane-dichloromethane (4:5) to provide the title compound (18 mg, 12% yield) as a white powder. ^1H NMR (CD_3OD) δ 8.79 (s, 1H), 7.91(s, 1H), 7.44 (br d, 2H), 7.18-7.38 (m, 4H), 2.52 (s, 3H).

10

EXAMPLE 34

N-(4-CHLORO-3-METHYLAMINO-PHENYL)-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of sodium hydride (60% in oil, 1.2 g, 30 mmol) in tetrahydrofuran (100 ml), cooled in an ice bath, was added slowly a solution of 2-
15 chloro-5-nitroaniline (5 g, 29 mmol) in tetrahydrofuran (10 ml) followed by a solution of iodomethane (1.8 ml, 29 mmol) in tetrahydrofuran (10 ml). After stirring at room temperature for 20 hours, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (100 ml) and water (100 ml). The organic layer was washed with saturated aqueous sodium
20 chloride solution (50 ml), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane-hexane (1:3) and recrystallized (ethyl ether) to provide (2-chloro-5-nitro-phenyl)-methyl-amine (1.8 g, 33% yield) as orange crystals.

25 A solution of tin dichloride (4.0 g, 21.1 mmol) and (2-chloro-5-nitro-phenyl)-methyl-amine (1.0 g, 5.4 mmol) in concentrated hydrochloric acid (10 ml) was stirred for 2 hours. The mixture was treated with ethyl acetate (50 ml) and adjusted to pH 7 by slow addition of 1 M aqueous sodium hydroxide solution. The organic layer was dried over sodium sulfate and concentrated under reduced
30 pressure to provide 4-chloro-N-3-methyl-benzene-1,3-diamine (800 mg, 95% yield).

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-chloro-N-3-methyl-benzene-1,3-diamine using the method described in Example 37 provided the title compound (28% yield). ^1H NMR

(DMSO- d_6) 9.47 (br s, 1H), 7.81 (s, 1H), 7.42 (d, 1H), 7.34 (d, $J = 8.2$ Hz, 1H), 7.15-7.30 (m, 4H), 7.12 (d, $J = 8.4$ Hz, 1H), 5.40 (m, 1H), 2.78 (s, 3H), 2.55 (s, 3H).

EXAMPLE 35

[6-(5-CHLORO-2-METHYL-PHENYL)-2-CHLORO-3-YL-[1,3,5]-TRIAZIN-4-YL]-
(4-AZIDO-PHENYL)-AMINE

5 A mixture of [6-(5-chloro-2-methyl-phenyl)-2,4-dichloro-[1,3,5]-triazine] (242 mg, 0.88 mmol), 4-azidoaniline hydrochloride (150 mg, 0.88 mmol), anhydrous tetrahydrofuran (8 ml), and *N,N*-diisopropylethylamine (227 mg, 1.76 mmol) was stirred for 3 hours. After concentrating under reduced pressure, the
10 residue was purified by flash chromatography on silica gel eluting with dichloromethane-hexane (1:1) to provide the title compound (279 mg, 85% yield) as a yellow powder. ^1H NMR (DMSO- d_6) δ 10.89 (br s, 1H), 7.95 (br d, 1H), 7.68-7.74 (m, 2H), 7.38-7.56 (m, 2H), 7.15-7.20 (m, 2H), 2.52 (s, 3H).

EXAMPLE 36

15 6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-AZIDO-PHENYL)-AMINO-[1,3,5]TRIAZINE-2,4-DIAMINE

To a saturated solution of ammonia in tetrahydrofuran (4 ml) was added [6-(5-chloro-2-methyl-phenyl)-2-chloro-3-yl-[1,3,5]-triazin-4-yl]-(4-azido-phenyl)-amine (56 mg, 0.15 mmol). After stirring for 16 hours, the mixture was
20 concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography eluting with methanol-dichloromethane-hexane (1:25:25) to provide the title compound (45 mg, 85% yield) as a white powder. ^1H NMR (DMSO- d_6) δ 9.71 (br s, 1H), 7.82 (br s, 2H), 7.75 (d, $J = 2.3$ Hz, 1H), 7.41 (dd, $J = 2.4, 8.2$ Hz, 1H), 7.31 (d, $J = 8.2$ Hz, 1H), 7.23 (br s, 2H), 7.04 (d, $J = 8.8$
25 Hz, 2H), 2.52 (s, 3H).

EXAMPLE 37

6-(5-CHLORO-2-METHYL-PHENYL)-N-INDAN-5-YL-[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine (550 mg, 2 mmol), 4-aminoindane (133 mg, 2 mmol), tetrahydrofuran (10 ml), and
30 *N,N*-diisopropylethylamine (0.52 ml, 3.0 mmol) was stirred for 18 hours. After diluting with tetrahydrofuran (10 ml), the mixture was washed with a solution

composed of saturated aqueous sodium chloride solution (10 ml) and 1 M hydrochloric acid (10 ml). The organic layer was treated with a solution of ammonia in methanol (7 M, 7 ml). After stirring for 16 hours, the mixture was concentrated under reduced pressure. The residue was dissolved in tetrahydrofuran (15 ml), washed with saturated aqueous sodium chloride solution (15 ml), and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate-hexane (1:3) to provide the title compound (120 mg, 34% yield for 2 steps). ¹H NMR (DMSO-d₆) 9.44 (br s, 1H), 7.77 (s, 1H), 7.64 (s, 1H), 7.42 (br s, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 7.14 (m, 3H), 2.85 (m, 4H), 2.52 (s, 3H), 2.04 (m, 2H).

EXAMPLE 38

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-ETHYL-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-ethylaniline using the method described in Example 37 provided the title compound (58% yield). ¹H NMR (DMSO-d₆) 9.49 (br s, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.66 (br s, 2H), 7.43 (dd, J = 8.2 Hz and 2.4 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 7.12-7.18 (m, 4H), 2.53-2.59 (m, 5H), 1.19 (t, J = 7.6 Hz, 3H).

EXAMPLE 39

6-(5-CHLORO-2-METHYL-PHENYL)-N-P-TOLYL-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and p-toluidine using the method described in Example 37 provided the title compound (47% yield). ¹H NMR (DMSO-d₆) 9.49 (br s, 1H), 7.77 (d, J = 2.4 Hz, 1H), 7.66 (br s, 2H), 7.44 (dd, J = 8.2 Hz and 2.4 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 7.09-7.18 (m, 4H), 2.52 (s, 3H), 1.51 (s, 3H).

EXAMPLE 40

N-(4-BROMOPHENYL)-6-(5-CHLORO-2-TRIFLUOROMETHYLPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

To a mixture of 5-chloro-2-trifluoromethylbenzoic acid (2.25 g, 10.0 mmol) and dichloromethane (40 ml) was added oxalyl chloride (1.1 ml, 12.6 mmol) followed by N,N-dimethylformamide (5 drops). After stirring for 90 minutes, methanol (5 ml) was added. After stirring for 30 minutes, the mixture was

concentrated under reduced pressure. The residue was dissolved in ethyl acetate (50 ml). The solution was washed with water (50 ml), washed with aqueous sodium carbonate solution (0.5 M, 2x 50 ml), dried over sodium sulfate, and concentrated under reduced pressure to provide 5-chloro-2-trifluoromethylbenzoate (2.14 g, 90% yield).

The reaction of 1-(4-bromophenyl)biguanidine hydrochloride with methyl 5-chloro-2-trifluoromethylbenzoate using the method described in Example 2 provided the title compound (40% yield). ¹H NMR (DMSO-d₆) δ 9.82 (br s, 1H), 7.75-7.88 (m, 5 H), 7.36-7.44 (m, 4 H).

10

EXAMPLE 41

{4-[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-aminobenzyl alcohol using the method described in Example 37 provided the title compound (50 mg, 62% yield). ¹H NMR (DMSO-d₆) 9.52 (br s, 1H), 7.77 (s, 1H), 7.70 (s, 2H), 7.42 (d, 1H), 7.33 (d, 1H), 7.24 (m, 4H), 5.07 (m, 1H), 4.45 (d, J = 5.7 Hz, 2H), 2.52 (s, 3H).

20

EXAMPLE 42

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-ETHYNYL-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-ethynylaniline using the method described in Example 37 provided the title compound (457 mg, 46% yield). ¹H NMR (DMSO-d₆) 9.82 (s, 1H), 7.87 (d, J = 8.1 Hz, 2H), 7.78 (d, J = 2.4 Hz, 1H), 7.32-7.45 (m, 6H), 4.07 (s, 1H), 2.53 (s, 3H).

25

EXAMPLE 43

5-[4-AMINO-6-(5-CHLORO-2-METHYLPHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-2-CHLORO-N-METHYLBENZAMIDE

To a mixture of 2-chloro-5-nitrobenzoic acid (5.0 g, 25.0 mmol) and dichloromethane (100 ml) was added oxalyl chloride (2.7 ml, 31.0 mmol) followed

30

by N,N-dimethylformamide (5 drops). After stirring for 2 hours, the mixture was concentrated under reduced pressure to provide 2-chloro-5-nitro-benzoyl chloride.

A mixture of 2-chloro-5-nitro-benzoyl chloride (502 mg, 2.3 mmol), methylamine hydrochloride (213 mg, 3.1 mmol), dichloromethane (10 ml), and triethylamine (0.84 ml, 6.0 mmol) was stirred for 60 hours. The mixture was treated with ethyl acetate (25 ml). The solution was washed with a mixture of saturated aqueous sodium chloride solution and 1 M hydrochloric acid (1:1, 2x 20 ml), washed with aqueous sodium carbonate solution (1 M, 20 ml), dried over sodium sulfate, and concentrated under reduced pressure to provide 2-chloro-N-methyl-5-nitro-benzamide.

To a suspension of 2-chloro-N-methyl-5-nitro-benzamide (2.3 mmol) in concentrated hydrochloric acid (3 ml) was added a solution of tin dichloride (1.4 g, 7.2 mmol) in concentrated hydrochloric acid (4 ml). After stirring for 20 hours, the mixture was cooled in an ice bath and treated with 50% sodium hydroxide to basic pH. The mixture was extracted with ethyl acetate (3x 25 ml). The combined extracts were dried over sodium sulfate and concentrated under reduced pressure to provide 5-amino-2-chloro-N-methylbenzamide (274 mg, 88% yield).

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 5-amino-2-chloro-N-methylbenzamide using the method described in Example 37 provided the title compound (222 mg, 55% yield). ¹H NMR (DMSO-d₆) δ 9.80 (br s, 1H), 8.32 (q, 1 H, J = 4 Hz), 7.86 (br s, 2 H), 7.78 (d, 1 H, J = 2 Hz), 7.31-7.44 (m, 5 H), 2.75 (d, 3 H, J = 4 Hz), 2.52 (s, 3 H).

EXAMPLE 44

6-(5-CHLORO-2-METHYLAMINOPHENYL)-N-(4-CHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of methyl 2-amino-5-chlorobenzoate (1.0 g, 5.4 mmol), iodomethane (0.75 ml, 12.0 mmol), potassium carbonate (1.7 g, 12.4 mmol), and acetonitrile (20 ml) was stirred for 48 hours. The mixture was filtered through a pad of celite under suction and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica eluting with ethyl acetate-hexane (1:19) to provide 5-chloro-2-methylaminobenzoic acid methyl ester (137 mg, 13% yield) followed by 5-chloro-2-dimethylaminobenzoic acid methyl ester (809 mg, 70% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride with methyl 5-chloro-2-methylaminobenzoate using the method described in Example 2

provided the title compound (179 mg, 25% yield). ¹H NMR (DMSO-d₆) δ 9.69 (br s, 1H), 9.18 (q, 1 H, J = 5 Hz), 8.35 (d, 1 H, J = 2 Hz), 7.79 (br s, 1 H), 7.22-7.37 (m, 5 H), 6.69 (d, 1 H, J = 9 Hz), 2.86 (d, 3 H, J = 5 Hz).

EXAMPLE 45

5 6-(5-BROMO-2-CHLORO-PHENYL)-N-(4-CHLORO-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of 5-bromo-2-chloro-benzoic acid (2.5 g, 10.6 mmol) in dichloromethane (50 ml) was added a solution of oxalyl chloride in dichloromethane (2 M, 6 ml, 12 mmol) followed by N,N-dimethylformamide (5 drops). After stirring for 30 minutes, methanol (10 ml) was added and the mixture was stirred for 20 hours. The mixture was concentrated under reduced pressure and partitioned between ethyl acetate (150 ml) and saturated aqueous potassium carbonate solution (100 ml). The organic layer was concentrated under reduced pressure to provide methyl 5-bromo-2-chloro-benzoate (2.4 g, 91% yield).

15 The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and methyl 5-bromo-2-chloro-benzoate using the method described in Example 2 provided the title compound (418 mg, 51% yield). ¹H NMR (DMSO-d₆) 9.85 (br s, 1H), 7.84 (m, 3H), 7.69 (m, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.40 (s, 2H), 7.33 (d, J = 8.9 Hz, 2H).

EXAMPLE 46

20 {4-[4-AMINO-6-(2,5-DICHLORO-PHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL

The reaction of 2,4-dichloro-6-(2,5-dichloro-phenyl)-[1,3,5]triazine and 4-aminobenzyl alcohol using the method described in Example 37 provided the title compound (560 mg, 77% yield). ¹H NMR (DMSO-d₆) 9.65 (br s, 1H), 7.74 (m, 3H), 7.60 (m, 2H), 7.26 (br s, 2H), 7.24 (d, J = 8.4 Hz, 2H), 5.05 (br s, 1H), 4.40 (s, 2H).

EXAMPLE 47

6-(5-CHLORO-2-DIMETHYLAMINOPHENYL)-*N*-(4-CHLOROPHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of methyl 2-amino-5-chlorobenzoate (1.0 g, 5.4 mmol),
5 iodomethane (0.75 ml, 12.0 mmol), potassium carbonate (1.7 g, 12.4 mmol), and
acetonitrile (20 ml) was stirred for 48 hours. The mixture was filtered through a
pad of celite under suction and the filtrate was concentrated under reduced
pressure. The residue was purified by flash chromatography on silica eluting with
ethyl acetate-hexane (1:19) to provide 5-chloro-2-methylaminobenzoic acid methyl
10 ester (137 mg, 13% yield) followed by 5-chloro-2-dimethylaminobenzoic acid
methyl ester (809 mg, 70% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride with
methyl 5-chloro-2-dimethylaminobenzoate using the method described in
Example 2 provided the title compound (110 mg, 20% yield). ¹H NMR (DMSO-d₆)
15 δ 9.72 (br s, 1H), 7.87 (d, 2 H, *J* = 9 Hz), 7.42 (br s, 1 H), 7.15-7.33 (m, 5 H), 6.96
(d, 1 H, *J* = 9 Hz), 2.70 (s, 6 H).

EXAMPLE 48

6-(2,5-DICHLORO-PHENYL)-*N*-(1H-INDAZOL-6-YL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(2,5-dichloro-phenyl)-[1,3,5]triazine
20 and 6-aminoindazole using the method described in Example 37 provided the title
compound (148 mg, 40% yield). ¹H NMR (DMSO-d₆) 12.85 (s, 1H) 9.83 (br s, 1H),
8.05 (s, 1H), 7.94 (s, 1H), 7.28 (s, 1H), 7.55-7.63 (m, 4H), 7.50 (s, 1H), 7.35 (s,
1H).

EXAMPLE 49

25 6-(2,5-DICHLORO-PHENYL)-*N*-*p*-TOLYL-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-methyl-phenyl)biguanidine hydrochloride with
methyl 2,5-dichlorobenzoate using the method described in Example 2 provided
the title compound (53 mg, 17% yield). ¹H NMR (DMSO-d₆) 9.62 (br s, 1H), 7.66-
7.70 (m, 3H), 7.54-7.60 (m, 2H), 7.30 (br s, 2H), 7.10 (d, *J* = 8.3 Hz, 2H), 2.26 (s,
30 3H).

EXAMPLE 50

N-(4-CHLORO-PHENYL)-6-(5-CHLORO-2-PROPOXY-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of 1-bromo-propane (1 ml, 11 mmol), methyl 5-chloro-2-hydroxy-benzoate (1.0 g, 5.4 mmol), potassium carbonate (1.5 g, 10.9 mmol), and acetonitrile (20 ml) was heated under reflux for 4 hours. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (100 ml) and saturated aqueous sodium chloride solution (50 ml). The organic layer was concentrated under reduced pressure to provide methyl 5-chloro-2-propoxy-benzoate (1.2 g, 97% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and methyl 5-chloro-2-propoxy-benzoate using the method described in Example 2 provided the title compound (270 mg, 35% yield). ¹H NMR (DMSO-d₆) 9.68 (br s, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.46 (s, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.31 (d, J = 8.8 Hz, 2H), 7.18 (br s, 2H), 7.14 (d, J = 8.8 Hz, 1H).

EXAMPLE 51

6-(5-CHLORO-2-ETHOXY-PHENYL)-N-(1H-INDAZOL-6-YL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazine and 6-aminoindazole using the method described in Example 37 provided the title compound (114 mg, 30% yield). ¹H NMR (DMSO-d₆) 12.82 (s, 1H), 9.71 (br s, 1H), 8.12 (s, 1H), 7.93 (s, 1H), 7.62 (d, J = 8.7 Hz, 1H), 7.52 (s, 1H), 7.47 (m, 2H), 7.16 (m, 3H), 4.13 (m, 2H), 1.26 (m, 3H).

EXAMPLE 52

6-(5-CHLORO-2-ISOPROPOXY-PHENYL)-N-(4-CHLORO-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of 2-iodo-propane (2.2 ml, 22 mmol), methyl 5-chloro-2-hydroxy-benzoate (2.0 g, 10.7 mmol), potassium carbonate (3.0 g, 10.9 mmol), and acetonitrile (40 ml) was heated under reflux for 3 hours. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (100 ml) and saturated aqueous sodium chloride solution (100 ml). The organic layer was

dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane-hexane (1:3 followed by 1:2 followed by 1:1) to provide methyl 5-chloro-2-isopropoxy-benzoate (1.2 g, 49% yield).

- 5 The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and methyl 5-chloro-2-isopropoxy-benzoate using the method described in Example 2 provided the title compound (230 mg, 29% yield). ¹H NMR (DMSO-d₆) 9.68 (br s, 1H), 7.88 (d, J = 8.9 Hz, 2H), 7.45 (s, 1H), 7.40 (m, 1H), 7.30 (d, J = 8.8 Hz, 2H), 7.18 (s, 2H), 7.15 (d, J = 8.9 Hz, 2H), 4.52 (m, 1H), 1.22 (m, 6H).

10

EXAMPLE 53

{4-[4-AMINO-6-(5-CHLORO-2-ETHOXY-PHENYL)
[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL

- 15 The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazine and 4-aminobenzyl alcohol using the method described in Example 37 provided the title compound (230 mg, 31% yield). ¹H NMR (DMSO-d₆) 9.55 (br s, 1H), 7.78 (d, J = 8.1 Hz, 2H), 7.51 (s, 1H), 7.46 (d, J = 8.8 Hz, 1H), 7.22 (d, J = 8.0, 2H), 7.15 (m, 3H), 5.06 (m, 1H), 4.44 (s, 2H), 4.10 (m, 2H), 3.61 (br s, 1H), 1.31 (m, 3H).

EXAMPLE 54

- 20 6-(5-CHLORO-2-ETHOXYPHENYL)-N-(4-NITROPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

- The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxyphenyl)-[1,3,5]triazine and 4-nitroaniline using the method described in Example 37 provided the title compound (586 mg, 73% yield). ¹H NMR (DMSO-d₆) δ 10.35 (br s, 1H), 8.12-8.19 (m, 4 H), 7.36-7.57 (m, 4 H), 7.17 (d, 1 H, J = 9 Hz), 4.12 (q, 2 H, J = 7 Hz), 1.29 (t, 3 H, J = 7 Hz).
- 25

EXAMPLE 55

N-BENZO[1.3]DIOXOL-5-YL-6-(5-CHLORO-2-ETHOXY-PHENYL)[1,3,5]TRIAZINE-2,4-DIAMINE

- 30 The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazine and 3,4-(methylenedioxy)-aniline using the method described in Example 37 provided the title compound (30 mg, 4% yield). ¹H NMR (DMSO-d₆)

9.50 (br s, 1H), 7.67 (s, 1H), 7.50 (s, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 8.8, 2H), 7.10 (m, 3H), 6.82 (d, J = 8.4 Hz, 1 H), 5.96 (s, 2H), 4.08 (m, 2H), 1.30 (m, 3H).

EXAMPLE 56

5 6-(5-CHLORO-2-ETHOXYPHENYL)-N-(4-NITROPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxyphenyl)-[1,3,5]triazine and 4-bromoaniline using the method described in Example 37 provided the title compound (261 mg, 53% yield). ¹H NMR (DMSO-d₆) δ 9.75 (br s, 1H), 7.83 (d, 2 H, J = 9 Hz), 7.43-7.52 (m, 4 H), 7.13-7.20 (m, 3 H), 4.09 (q, 3 H, J = 7 Hz), 1.28 (t, 3 H, J = 7 Hz).

EXAMPLE 57

2-{4-[4-AMINO-6-(5-CHLORO-2-METHYL-PHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-ETHANOL

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-aminophenethyl alcohol using the method described in Example 37 provided the title compound (150 mg, 42% yield). ¹H NMR (DMSO-d₆) 9.48 (br s, 1H), 7.76 (s, 1H), 7.64 (s, 2H), 7.43 (m, 1H), 7.32 (m, 1H), 7.16 (s, 2H), 7.13 (d, J = 8.2 Hz, 2H), 4.61 (s, 1H), 3.58 (t, J = 7.1 Hz, 2H), 2.69 (t, J = 6.9 Hz, 2H), 2.52 (s, 3H).

EXAMPLE 58

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-DIMETHYLAMINOMETHYL-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of 4-nitrobenzyl bromide (2.16 g, 10 mmol), a solution of dimethylamine in methanol (2 M, 50 ml, 100 mmol), N, N-dimethylformamide (20 ml), and potassium carbonate (2.07 g, 15 mmol) was stirred for 12 hours. The methanol was removed by concentrating under reduced pressure and the mixture was treated with ethyl acetate (200 ml). The mixture was washed with water (100 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to yield 4-(N, N-dimethylaminomethyl)-4-nitrobenzene (0.98 g, 72% yield).

A mixture of 4-(N, N-dimethylaminomethyl)-4-nitrobenzene (0.98 g, 5.8 mmol), ethyl acetate (50 ml), and 10% palladium on carbon (200 mg) was treated with hydrogen gas (40 psi) on a Parr shaker for 1 hour. The mixture was filtered through a pad of celite under suction and the filtrate was concentrated under reduced pressure to yield 4-(N,N-dimethylaminomethyl)-aniline (0.77 g, 97 % yield).

A solution of 2,4-dichloro-6- (5-chloro-2-methyl-phenyl)-[1,3,5] triazine (275 mg, 1 mmol), 4-N,N-dimethylaminomethylaniline (150 mg, 1 mmol), tetrahydrofuran (10 ml), and N,N-diisopropylethylamine (129 mg, 1 mmol) was stirred for 4 hours. After concentrating under reduced pressure, the residue was dissolved in ethyl acetate (15 ml). The solution was washed with cold hydrochloric acid (1 M, 10 ml), washed with water (10 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 5% methanol-ethyl acetate to provide [4-chloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]-triazin-2-yl]-(4-dimethylaminomethyl-phenyl)-amine (0.305 g, 78% yield). ¹H NMR (CDCl₃) δ 8.0 (s, 1H), 7- 7.8 (m, 6H), 3.3 (d, 6H) 2.6 (s, 3H).

A pressure bottle was charged with [4-chloro-6- (5-chloro-2-methyl-phenyl)-[1,3,5]-triazin-2-yl]-(4-dimethylaminomethyl-phenyl)-amine (0.305 g, 0.79 mmol) and tetrahydrofuran (20 ml) and cooled to -78°C. A slow stream of ammonia gas was passed into the solution for 2 minutes and the bottle was sealed. After stirring at room temperature for 12 hours, the mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 10% methanol-ethyl acetate to provide the title compound (0.148 g, 49% yield). ¹H NMR (CDCl₃) δ 7.9 (s, 1H), 7.2-7.6 (m, 6H), 3.25 (d, 6H) 2.5 (s, 3H).

EXAMPLE 59

6-(5-CHLORO-2-METHYL-PHENYL)-N-(3,4-DIMETHYL-PHENYL)- [1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 3,4-dimethylaniline using the method described in Example 37 provided the title compound (215 mg, 63% yield). ¹H NMR (DMSO-d₆) 9.39 (br s, 1H), 7.79 (s, 1H), 7.54 (s, 1 H), 7.48 (br s, 2H), 7.43 (m, 1 H), 7.33 (m, 1H), 7.15 (br s, 2H), 7.05 (m, 1H), 2.54 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H).

EXAMPLE 60

{4-[4-AMINO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YLAMINO]-PHENYL}-ACETIC ACID

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-
5 [1,3,5]triazine and 4-aminophenylacetic acid using the method described in
Example 37 provided the title compound (265 mg, 72% yield). ¹H NMR (DMSO-d₆)
12.21 (br s, 1H), 9.53 (br s, 1H), 7.76 (m, 1H), 7.70 (m, 2H), 7.43 (m, 1H), 7.32 (m,
1H), 7.17 (m, 4H), 3.50 (s, 2H), 2.52 (s, 3H).

EXAMPLE 61

10 6-(5-CHLORO-2-ETHOXYPHENYL)-*N*-*P*-TOLYL-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxy-phenyl)-
[1,3,5]triazine and *p*-toluidine using the method described in Example 37 provided
the title compound (73 mg, 20% yield). ¹H NMR (DMSO-d₆) 9.50 (br s, 1H), 7.71
(d, *J* = 8.4 Hz, 2H), 7.43-7.50 (m, 2H), 7.15 (dd, *J* = 24.0, 8.6 Hz, 5H), 4.11 (q, *J* =
15 6.8 Hz, 2H), 2.25 (s, 3H), 1.30 (t, *J* = 6.9 Hz, 3H).

EXAMPLE 62

5-[4-AMINO-6-(5-CHLORO-2-ETHOXYPHENYL)-[1,3,5]TRIAZIN-2-YLAMINO]-
2-CHLORO-*N*-METHYLBENZAMIDE

20 5-Amino-2-chloro-*N*-methylbenzamide was synthesized by the
method described in Example 43.

The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxyphenyl)-
[1,3,5]triazine and 5-amino-2-chloro-*N*-methylbenzamide using the method
described in Example 37 provided the title compound (147 mg, 35% yield). ¹H
NMR (DMSO-d₆) δ 9.78 (br s, 1H), 8.30 (q, 1 H, *J* = 5 Hz), 7.85-7.99 (m, 2 H),
25 7.14-7.52 (m, 6 H), 4.08 (q, 2 H, *J* = 7 Hz), 2.77 (d, 3 H, *J* = 8 Hz), 1.27 (t, 3 H, *J* =
7 Hz).

EXAMPLE 63

(*S*)-2-AMINO-PENTANEDIOIC ACID 5-[4-[4-AMINO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YLAMINO]-BENZYL} ESTER

30 A mixture of the title compound of Example 41 (1.0 g, 2.92 mmol), *N*-
butoxycarbonyl glutamic acid α-*tert*-butyl ester (0.975 g, 3.22 mmol), *N,N*-

dimethylaminopyridine (0.071 g, 0.58 mmol), *N,N*-dimethylformamide (10 ml), and *N,N*-diisopropylcarbodiimide (0.479 g, 3.8 mmol) was stirred for 12 hours. The mixture was treated with water (100 ml) and extracted with ethyl acetate (4x 50 ml). The combined extracts were washed with water (2x 50 ml), dried over
5 magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with 30% ethyl acetate-hexane to provide 2-*tert*-butoxycarbonylamino-pentanedioic acid 5-{4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5] triazin-2-ylamino]-benzyl} ester 1-*tert*-butyl ester (1.45 g, 79%
10 yield). ¹H NMR (CDCl₃) δ 7.78 (s, 1H), 7.58-7.60 (br s, 2H), 7.30-7.34 (m, 4H), 7.19-7.21 (d, 1H), 5.3-5.5 (br s, 2H), 5.10-5.2 (br s, 1H) 5.10 (s, 2H) 4.2-4.3 (m, 1H) 2.55 (s, 3H) 2.3-2.5 (m, 2H), 2.1-2.25 (m, 1H) 1.85-2 (m, 1H) 1.45 (s, 9H) 1.40 (s, 9H).

A mixture of 2-*tert*-butoxycarbonylamino-pentanedioic acid 5-{4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl} ester 1-*tert*-
15 butyl ester (1.45 g, 2.3 mmol), acetic acid (10 ml), dichloromethane (5 ml), and a solution of hydrogen chloride in 1,4-dioxane (4 M, 10 ml) was stirred for 12 hours. The mixture was poured into ethyl acetate (50 ml). The solid was filtered and dried under reduced pressure to provide the hydrochloride salt of the title compound (0.98 g, 75% yield). ¹H NMR (CD₃OD) δ 7.78 (s, 1H), 7.7-7.9 (br s, 2H), 7.58 (d,
20 2H), 7.46 (d, 4H), 5.18 (s, 2H) 4.09 (t, 1H) 2.58-2.82 (m, 2H) 2.58 (br s, 3H), 2.1-2.3 (m, 2H).

EXAMPLE 64

(S)-2-AMINO-PENTANEDIOIC ACID 1-{4-[4-AMINO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]-TRIAZIN-2-YLAMINO]-BENZYL} ESTER

25 The title compound was synthesized according to the method described in Example 63 using the title compound of Example 41 and *N*-*tert*-butoxycarbonyl glutamic acid γ-*tert*-butyl ester (74% yield). ¹H NMR (CD₃OD) δ 7.75-8 (br s, 2 H), 7.75 (s, 1H), 7.59 (d, 2H), 7.5 (d, 4H), 7.45 (d, 2H), 5.32 (s, 2H) 4.11 (t, 1H) 2.55 (s, 3H) 2.45-2.56 (m, 2H), 2.1-2.25 (m, 2H).

EXAMPLE 65

6-[5-CHLORO-2-(2-METHOXY-ETHOXY)-PHENYL]-N-(4-CHLORO-PHENYL)
[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of 5-chlorosalicylic acid (5.0 g, 29.0 mmol), potassium
5 carbonate (10.8 g, 78.1 mmol), acetonitrile (100 ml), and 2-bromoethylmethyl ether
(6.8 ml, 72.3 mmol) was heated under reflux for 20 hours. The mixture was filtered
and the filtrate was concentrated under reduced pressure. The residue was
dissolved in ethyl acetate (50 ml). The solution was washed with aqueous sodium
hydroxide solution (1 M, 2x 50 ml), washed with water (50 ml), dried over sodium
10 sulfate, and concentrated under reduced pressure to provide 5-chloro-2-(2-
methoxyethoxy)benzoic acid 2-methoxyethyl ester (7.83 g, 93% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and
methoxyethyl 5-chloro-2-(2-methoxy-ethoxy)-benzoate using the method described
in Example 2 provided the title compound (530 mg, 65% yield). ¹H NMR (DMSO-
15 d₆) 9.70 (br s, 1H), 7.87 (d, J = 8.9 Hz, 2H), 7.50 (s, 1H), 7.45 (m, 1H), 7.32 (d, J =
8.9 Hz, 2H), 7.20 (s, 2H), 7.17 (d, J = 8.9 Hz, 2H), 4.15 (m, 2H), 3.61 (m, 2H), 3.22
(m, 3H).

EXAMPLE 66

6-(5-CHLORO-2-METHYL-PHENYL)-N-(3-ETHYL-PHENYL)-
20 [1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-
[1,3,5]triazine and 3-ethylaniline using the method described in Example 37
provided the title compound (80 mg, 24% yield). ¹H NMR (DMSO-d₆) 9.48 (br s,
1H), 7.79 (s, 1H), 7.63 (s, 2H), 7.42 (d, J = 8.2 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H),
25 7.20 (m, 3H), 6.85 (d, J = 7.4 Hz, 1H), 2.61 (q, J = 7.5 Hz, 2H), 2.53 (s, 3H), 1.21
(t, J = 7.6 Hz, 3H).

EXAMPLE 67

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-VINYL-PHENYL)-[1,3,5] TRIAZINE-2,4-DIAMINE

A mixture of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine
30 (500 mg, 1.8 mmol), 4-vinylphenylamine (228 mg, 1.9 mmol), tetrahydrofuran (20
ml), and *N,N*-diisopropylethylamine (0.63 ml, 3.6 mmol) was stirred for 2 hours.
The mixture was transferred to a pressure bottle and chilled to -78°C. A slow

stream of ammonia gas was passed into the mixture for 2 minutes and the bottle was sealed. After stirring at room temperature for 60 hours, the mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate-hexane (1:3) to provide the
5 title compound (260 mg, 41% yield). ¹H NMR (acetone-d₆) 8.78 (br s, 1H), 7.92 (d, J = 2.4 Hz, 1H), 7.88 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.6 Hz, 2H), 7.39 (dd, J=2.4 Hz, J=8.2 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 6.74 (dd, J=11.0 Hz, J=17.6 Hz, 1H), 6.64 (br s, 1H), 5.73 (dd, J=1.0 Hz, J=17.6 Hz, 1H), 5.15 (dd, J=1.0 Hz, J=11.0 Hz, 1H), 2.61 (s, 3H).

10

EXAMPLE 68

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-FLUOROMETHYL-PHENYL)-
[1,3,5]-TRIAZINE-2, 4-DIAMINE

To a solution of the title compound of Example 41 (0.185 g, 0.48 mmol) in dichloromethane (3 ml) and tetrahydrofuran (15 ml), cooled at -78°C,
15 was added (diethylamino) sulfur trifluoride (0.081 g). After stirring at -78°C for 2 hours, the mixture was treated with water (50 ml) and extracted with ethyl acetate (3x 30 ml). The combined extracts were washed with water (25 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The
20 residue was purified by preparative thin layer chromatography eluting with 20% ethyl acetate-hexane to provide the title compound (23 mg, 14% yield). ¹H NMR (CDCl₃) δ 7.8 (d, 1H), 7.64 (d, 2H), 7.39- 7.20(m, 4H), 5.3-5.43(d, 2H), 5.35 (br s, 2H), 2.56 (s, 3H).

EXAMPLE 69

1-{4-[4-AMINO-6-(5-CHLORO-2-ETHOXY-PHENYL)-]-
25 [1,3,5] TRIAZIN-2-YLAMINO]-PHENYL}-ETHANE-1,2-DIOL

The reaction of 2,4-dichloro-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazine and 4-vinylphenylamine using the method described in Example 67 provided 6-(5-chloro-2-ethoxy-phenyl)-N-(4-vinyl-phenyl)-[1,3,5]triazine-2,4-diamine.

30

A mixture of 6-(5-chloro-2-ethoxy-phenyl)-N-(4-vinyl-phenyl)-[1,3,5]triazine-2,4-diamine (150 mg, 0.52 mmol), acetone (15 ml), water (5 ml), 4-methyl-morpholin-4-ol (50% in water, 1 ml), and potassium osmate dihydrate (5 mg, 0.01 mmol) was stirred for 12 hours. The mixture was concentrated under

reduced pressure. The residue was purified by flash chromatography eluting with hexane-ethyl acetate (1:3) followed by ethyl acetate to provide the title compound (120 mg, 55% yield). ¹H NMR (DMSO-d₆) δ 9.52 (br s, 1H), 7.73 (d, J = 8.6 Hz, 2H), 7.50 (br s, 1H), 7.44 (dd, J=2.7 Hz, J=8.8 Hz, 1H), 7.22 (d, J = 8.5 Hz, 2H), 7.15-7.05 (m 3H), 5.11 (br s, 1H), 4.66 (br s, 1H), 4.48 (br s, 1H), 4.08 (q, J = 6.9 Hz, 2H), 3.40 (br s, 2H), 1.49 (t, J = 6.9 Hz, 3H).

EXAMPLE 70

SUCCINIC ACID MONO- {4-[4-AMINO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YLAMINO]-BENZYL ESTER

10 A mixture of the title compound of Example 41 (0.684 g, 2.0 mmol), succinic anhydride (0.25 g, 2.5 mmol), *N,N*-disopropylethylamine (0.387 g, 3 mmol), dimethylformamide (5 ml), and ethyl acetate (10 ml) was heated at 70°C for 12 hours. The mixture was treated with ethyl acetate (150 ml) and cold hydrochloric acid (1 M, 50 ml). The organic layer was dried over anhydrous
15 magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 20% hexane-ethyl acetate to provide the title compound (0.34 g, 38% yield). ¹H NMR (CD₃OD) δ 7.68-7.72 (m, 3 H), 7-7.33 (m, 4H), 5.22 (s, 2H) 2.56-2.62 (m, 4H), 2.47 (s, 3H).

EXAMPLE 71

20 AMINO-ACETIC ACID 4-[4-AMINO-6- (5-CHLORO-2-METHYL-PHENYL)-
[1,3,5] TRIAZIN-2-YLAMINO]-BENZYL ESTER

A mixture of the title compound of Example 41 (0.684 g, 2.0 mmol), *N*-tert-butoxycarbonyl glycine (0.368g, 2.1 mmol), *N,N*-dimethylaminopyridine (0.049 g, 0.4 mmol), dimethylformamide (15 ml), and *N,N*-diisopropylcarbodiimide
25 (0.278 g, 2.2 mmol) was stirred for 12 hours. The mixture was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with 40% ethyl acetate-hexane to provide 2-tert-butoxycarbonylamino-acetic acid 4-[4-amino-6- (5-chloro-2-methyl-phenyl)-[1,3,5] triazin-2-yl-amino]-benzyl ester (1.05 g, 100 % yield). ¹H NMR (CDCl₃) δ 7.74 (s, 1H), 7.63-7.74 (d, 1H), 7.6 (br s, 2H),
30 7.31-7.36(m, 4H), 7.20-7.22 (d, 1H), 5.3-5.6(br s, 2H), 5.17 (d, 2H) 4.95-5.1 (br s, 1H), 3.965 (d, 2H), 2.55 (s, 3H), 1.47 (s, 9H).

A mixture of 2-tert-butoxycarbonylamino-acetic acid 4-[4-amino-6- (5-chloro-2-methyl-phenyl)-[1,3,5] triazin-2-yl-amino]-benzyl ester (1.0 g, 2 mmol), dichloromethane (20 ml), and a solution of hydrogen chloride in 1,4-dioxane (4 M, 5 ml) was stirred for 12 hours. The reaction mixture was poured into ethyl acetate (100 ml). The solid filtered and dried under reduced pressure to provide the hydrochloride salt of the title compound (0.38 g, 84% yield). ¹H NMR (CD₃OD) δ 7.75-8 (br s, 2 H), 7.74 (s, 1H), 7.56-7.43(m, 6H), 5.36 (s, 2H) 3.67 (s, 2H) 2.58 (s, 3H).

EXAMPLE 72

(S)-2-AMINO-SUCCINIC ACID 1-{4-[4-AMINO-6- (5-CHLORO-2-METHYL-PHENYL)-[1,3,5] TRIAZIN-2-YLAMINO]-BENZYL} ESTER

The title compound was synthesized according to the method described in Example 71 using the title compound of Example 41 and *N*-butoxycarbonyl aspartic acid γ-tert-butyl ester (75% yield). ¹H NMR (CD₃OD) δ 7.6-7.99 (br s, 2 H), 7.63-7.33(m, 7H), 5.18-5.26 (m, 2H) 4.3 (t, 1H) 2.90-2.96 (m, 2H), 2.47 (s, 3H).

EXAMPLE 73

(S)-2-AMINO-SUCCINIC ACID 4-{4-[4-AMINO-6- (5-CHLORO-2-METHYL-PHENYL)-[1,3,5] TRIAZIN-2-YLAMINO]-BENZYL} ESTER

The title compound was synthesized according to the method described in Example 71 using the title compound of Example 41 and *N*-butoxycarbonyl aspartic acid α-tert-butyl ester (81% yield). ¹H NMR (CD₃OD) δ 7.79-7.88 (br s, 2 H), 7.69-7.79 (d, 1H), 7.54-7.39 (m, 6H), 5.20 (s, 2H) 4.31-4.34 (t, 1H) 3.06-3.08 (m, 2H), 2.53 (s, 3H).

EXAMPLE 74

{4-[4-(5-CHLORO-2-METHYL-PHENYL)-6-METHYLAMINO-[1,3,5]-TRIAZIN-2-YLAMINO]-PHENYL}-METHANOL

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-aminobenzyl alcohol using the method described in Example 67 and using methylamine in place of ammonia provided the title compound (81% yield). ¹H NMR (acetone-*d*₆) δ 8.75, 8.62 (2br s, 1H), 8.02-7.82

(m, 3H), 7.41-7.28 (m, 4H), 6.83 (br s, 1H), 4.62-4.59 (m, 2H), 4.10-4.05 (m, 1H), 3.05, 3.01 (2s, 3 H), 2.67, 2.59 (2s, 3H).

EXAMPLE 75

(S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID 4-[4-AMINO-6-
5 (5-CHLORO-2-METHYL-PHENYL)-[1,3,5] TRIAZIN-2-YLAMINO]-BENZYL ESTER

The title compound was synthesized according to the method described in Example 71 using the title compound of Example 41 and *N*-tert-butoxycarbonylamino-5- (N^9 , N^9 -di-tert-butoxycarbonyl)-L-arginine (54% yield). ^1H NMR (CD_3OD) δ 7.9- 7.7 (br s, 2 H), 7.70 (s, 1H), 7.56-7.41 (m, 6H), 5.31 (s, 2H)
10 4.15 (t, 1H) 3.22-3.30 (m, 2H), 2.54 (s, 3H) 1.5-2.1 (m, 4H).

EXAMPLE 76

(S)-PYRROLIDINE-2-CARBOXYLIC ACID 4-[4-AMINO-6- (5-CHLORO-2-METHYL-PHENYL)-
[1,3,5] TRIAZIN-2-YLAMINO]-BENZYL ESTER

The title compound was synthesized according to the method
15 described in Example 71 using the title compound of Example 41 and *N*-tert-butoxycarbonylamino- L-proline (79% yield). ^1H NMR (CD_3OD) δ 7.4- 7.99 (m, 7 H), 5.30-5.20 (m, 2H) 4.46-4.47(t, 1H) 2.90-3.4 (m, 2H), 2.52 (s, 3H), 2.4-2.52 (m, 1H) 2.1-2.5 (m, 4H).

EXAMPLE 77

20 2-AMINO-PROPIONIC ACID 4-[4-AMINO-6- (5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]-TRIAZIN-2-YLAMINO]-BENZYL ESTER

The title compound was synthesized according to the method described in Example 71 using the title compound of Example 41 and *N*-tert-butoxycarbonylamino-L-alanine (73% yield). ^1H NMR (CD_3OD) δ 7.4- 7.99 (m, 8
25 H), 5.30-5.20 (m, 2H) 4.10-4.14(t, 1H), 2.52 (s, 3H), 1.52-1.54 (d, 3H).

EXAMPLE 78

6-(5-CHLORO-2-METHYL-PHENYL)-N-(4-METHOXY-METHYL-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

A mixture of (4-nitro-phenyl)-methanol (3.0 g, 19.6 mmol), potassium
30 carbonate (3.9 g, 28.1 mmol), acetonitrile (100 ml), and iodomethane (11 ml, 176

mmol) was heated at 50°C for 48 hours. The mixture was concentrated under reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and saturated aqueous sodium chloride solution (100 ml). The organic layer was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with hexane-dichloromethane (1:1 followed by 1:2) to yield 1-methoxymethyl-4-nitro-benzene (1.0 g, 31% yield).

A mixture of 1-methoxymethyl-4-nitro-benzene (1.0 g, 0.6 mmol), ethyl alcohol (20 ml), and 10% palladium on carbon (100 mg) was treated with hydrogen gas (40 psi) on a Parr shaker for 4 hours. The mixture was filtered through a pad of celite under suction. The filtrate was concentrated under reduced pressure to yield 4-methoxy-methyl-phenylamine (750 mg, 91% yield).

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine and 4-methoxymethylphenylamine using the method described in Example 37 provided the title compound (45 mg, 13% yield). ¹H NMR (DMSO-d₆) 9.60 (br s, 1H), 7.77 (m, 1H), 7.44 (s, 2H), 7.40-7.43 (m, 2H), 7.32 (m, 1H), 7.21-7.23 (m, 4H), 4.34 (s, 2H), 3.26 (s, 3H), 2.52 (s, 3H).

EXAMPLE 79

6-(5-CHLORO-2-METHOXY-PHENYL)-N-P-TOLYL-[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 1-(4-methyl-phenyl)biguanidine hydrochloride with methyl 5-chloro-2-methoxybenzoate using the method described in Example 2 provided the title compound (2.225 g, 49% yield). ¹H NMR (DMSO-d₆) 9.52 (br s, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.47-7.53 (m, 2H), 7.07-7.16 (m, 5H), 3.80 (s, 3H), 2.26 (s, 3H).

EXAMPLE 80

6-(2-BROMO-5-CHLORO-PHENYL)-N-(4-CHLORO-PHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of 2-bromo-5-chloro-benzoic acid (2.5 g, 10.6 mmol) in dichloromethane (50 ml) was added a solution of oxalyl chloride in dichloromethane (2 M, 6 ml, 12 mmol) followed by N,N-dimethylformamide (5 drops). After stirring for 30 minutes, methanol (10 ml) was added. After stirring for 3 hours, the mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (150 ml) and saturated aqueous potassium carbonate solution (100 ml). The organic layer was concentrated under reduced

pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane-hexane (1:2) to provide methyl 2-bromo-5-chloro-benzoate (2.1 g, 79% yield).

5 The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and methyl 2-bromo-5-chloro-benzoate using the method described in Example 2 provided the title compound (58% yield). ¹H NMR (DMSO-d₆) 9.87 (br s, 1H), 7.86 (d, J = 8.3 Hz, 2H), 7.76 (d, J = 8.3 Hz, 1H), 7.66 (m, 1H), 7.49 (m, 1H), 7.40 (br s, 2H), 7.34 (d, J = 8.8 Hz, 2H).

EXAMPLE 81

10 N-(4-CHLORO-PHENYL)-6-(2-CHLORO-5-TRIFLUOROMETHYL-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of 2-chloro-5-trifluoromethyl-benzoic acid (2.8 g, 12.5 mmol) in dichloromethane (50 ml) was added a solution of oxalyl chloride in dichloromethane (2 M, 7 ml, 14 mmol) followed by N,N-dimethylformamide (5 drops). After stirring for 2 hours, methanol (10 ml) was added. After stirring for 20 hours, the mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (200 ml) and saturated aqueous potassium carbonate solution (100 ml). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to provide methyl 2-chloro-5-trifluoromethyl-benzoate (2.6 g, 87% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and methyl 2-chloro-5-trifluoromethyl-benzoate using the method described in Example 2 provided the title compound (34% yield). ¹H NMR (DMSO-d₆) 9.89 (br s, 1H), 8.01 (m, 1H), 7.81-7.88 (m, 4H), 7.45 (d, 2H), 7.35 (d, J = 8.9 Hz, 2H).

EXAMPLE 82

25 N-BENZO[1.3]DIOXOL-5-YL-6-(2,5-DICHLORO-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

The reaction of 2,4-dichloro-6-(2,5-dichloro-phenyl)-[1,3,5]triazine and 3,4-(methylenedioxy)-aniline using the method described in Example 37 provided the title compound (8% yield). ¹H NMR (DMSO-d₆) 9.63 (br s, 1H), 7.70 (s, 1H), 7.54-7.60 (m, 3H), 7.30 (br s, 2H), 7.09 (s, 1H), 6.85 (d, J = 8.3 Hz, 1H), 5.60 (s, 2H).

EXAMPLE 83

6-(2-CHLORO-5-METHYL-PHENYL)-N-(4-CHLORO-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of 2-chloro-5-methyl-benzoic acid (3.0 g, 17.6
5 mmol) in dichloromethane (50 ml) was added a solution of oxalyl chloride in
dichloromethane (2 M, 10 ml, 20 mmol) followed by N,N-dimethylformamide (5
drops). After stirring for 1 hour, methanol (20 ml) was added. After stirring for 3
hours, the mixture was concentrated under reduced pressure. The residue was
partitioned between ethyl acetate (200 ml) and saturated aqueous potassium
10 carbonate solution (100 ml). The organic layer was concentrated under reduced
pressure to provide methyl 2-chloro-5-methyl-benzoate (3.2 g, 100% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and
methyl 2-chloro-5-methyl-benzoate using the method described in Example 2
provided the title compound (40% yield). ¹H NMR (DMSO-d₆) 9.80 (br s, 1H), 7.87
15 (d, J = 8.6 Hz, 2H), 7.40-7.43 (m, 2H), 7.27-7.33 (m, 5H), 2.34 (s, 3H).

EXAMPLE 84

[4-CHLORO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YL]-(1H-INDAZOL-5-YL)-AMINE

The reaction of 2,4-dichloro-6-(5-chloro-2-methyl-phenyl)-
20 [1,3,5]triazine and 5-aminoindazole using the method described in Example 37
provided the title compound (7% yield). ¹H NMR (DMSO-d₆) 12.95 (s, 1H), 9.52
(br s, 1H), 8.25 (s, 1H), 7.94 (s, 1H), 7.75 (m, 1H), 7.52 (m, 2H), 7.35-7.45 (m, 3H),
7.30 (m, 1H), 7.12 (br s, 2H), 2.50 (s, 3H).

EXAMPLE 85

25 6-(5-CHLORO-2-FLUORO-PHENYL)-N-(4-CHLORO-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of 5-chloro-2-fluoro-benzoic acid (2.0 g, 11.5 mmol)
in dichloromethane (50 ml) was added a solution of oxalyl chloride in
dichloromethane (2 M, 6.5 ml, 13 mmol) followed by N,N-dimethylformamide (5
30 drops). After stirring for 1 hour, methanol (10 ml) was added. After stirring for 20
hours, the mixture was concentrated under reduced pressure. The residue was
partitioned between ethyl acetate (200 ml) and saturated aqueous potassium

carbonate solution (100 ml). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to provide methyl 5-chloro-2-fluoro-benzoate (2.0 g, 92% yield).

5 The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and methyl 5-chloro-2-fluoro-benzoate using the method described in Example 2 provided the title compound (50% yield). ¹H NMR (DMSO-d₆) 9.80 (br s, 1H), 7.98 (m, 1H), 7.88 (d, J = 8.7 Hz, 2H), 7.62 (m, 1H), 7.30-7.40 (m, 5H).

EXAMPLE 86

10 6-(2-BROMO-5-METHYL-PHENYL)-N-(4-CHLORO-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

To a suspension of 2-bromo-5-methyl-benzoic acid (3.0 g, 14 mmol) in dichloromethane (100 ml) was added a solution of oxalyl chloride in dichloromethane (2 M, 8 ml, 16 mmol) followed by N,N-dimethylformamide (5 drops). After stirring for 30 minutes, methanol (15 ml) was added. After stirring for
15 3 hours, the mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (200 ml) and saturated aqueous potassium carbonate solution (100 ml). The organic layer was concentrated under reduced pressure to provide methyl 2-bromo-5-methyl-benzoate (3.2 g, 99% yield).

The reaction of 1-(4-chlorophenyl)biguanidine hydrochloride and
20 methyl 2-bromo-5-methyl-benzoate using the method described in Example 2 provided the title compound (43% yield). ¹H NMR (DMSO-d₆) 9.79 (br s, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.2 Hz, 1H), 7.38 (s, 1H), 7.25-7.30 (m, 4H), 7.20 (m, 1H), 2.31 (s, 3H).

EXAMPLE 87

25 4-[4-AMINO-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZIN-2-YLAMINO]-BENZALDEHYDE

To a suspension of the title compound of Example 41 (375 mg, 1.1 mmol) in dichloromethane (100 ml) was added pyridinium chlorochromate (810 mg, 2.7 mmol) and crushed molecular sieves (1.25 g, 3A). After stirring for 6
30 hours, diethyl ether (150 ml) was added and the mixture was filtered through a pad of silica gel under suction. The filtrate was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with ethyl acetate-hexane (1:3 followed by 1:2 followed by 1:1) to provide the title compound (25 mg,

7% yield). ¹H NMR (DMSO-d₆) 10.10 (s, 1H), 9.86 (s, 1H), 8.07 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 8.6 Hz, 2H), 7.79 (s, 1H), 7.43 (m, 2H), 7.34 (m, 2H), 2.53 (s, 3H).

EXAMPLE 88

N-(4-CHLOROMETHYL-PHENYL)-6-(5-CHLORO-2-METHYL-PHENYL)-
[1,3,5]TRIAZINE-2,4-DIAMINE

5

A solution of the title compound of Example 41 (2.25 g, 6.6 mmol) and thionyl chloride (1.2 g; 10 mmol) in tetrahydrofuran (40 ml) was heated at reflux for 6 hours. The mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (100 ml). The solution was washed with
10 10% aqueous sodium bicarbonate solution (2x 30 ml), washed with water (30 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate-hexane (1:1) to provide the title compound (1.2 g, 50% yield). ¹H NMR (CDCl₃) δ (ppm): 7.79 (s, 1H), 7.60-7.62 (d, 2H), 7.19-7.38 (m, 5H), 5.2-5.4 (br s,
15 2H), 4.6 (s, 2H), 2.55 (s, 3H).

EXAMPLE 89

4-[4-AMINO-6-(2,5-DICHLOROPHENYL)-[1,3,5]
TRIAZIN-2-YLAMINO]-BENZONITRILE

The reaction of 1-(4-cyano-phenyl)biguanidine hydrochloride with
20 methyl 2,5-dichlorobenzoate using the method described in Example 2 provided the title compound (94 mg, 21% yield). ¹H NMR (DMSO-d₆) 10.22 (br s, 1H), 8.07 (d, J = 8.7 Hz, 2H), 7.77-7.72 (m, 3H), 7.63-7.49 (m, 4H).

EXAMPLE 90

N-(3-CHLOROPHENYL)-6-(2,5-DICHLOROPHENYL)-[1,3,5]TRIAZINE-2,4-DIAMINE

25 The reaction of 1-(3-chlorophenyl)biguanidine hydrochloride and methyl 2,5-dichlorobenzoate using the method described in Example 2 provided the title compound (60 mg, 16% yield). ¹H NMR (DMSO-d₆) 9.88 (br s, 1H), 8.03 (s, 1H), 7.72-7.76 (m, 1H), 7.55-7.61 (m, 2H), 7.45 (br s, 2H), 7.26-7.32 (m, 2H), 7.01-7.07 (m, 1H).

EXAMPLE 91

LPAAT- β ASSAY

A. Production of recombinant LPAAT- β for Assays

For the construction of Baculovirus expression vectors, the full-length
5 human LPAAT- β cDNA was amplified by PCR from the DNA template
pCE9.LPAAT- β (West *et al.*, *DNA Cell Biol.* 16:691-701 (1997)) using the primers
5'-TGATATCCGA AGAAGATCTT ATGGAGCTGT GGCCGTGTC-3' (olpb1F) and
5'-CAGGCTCTAG ACTACTGGGC CGGCTGCAC-3' (olpb1R). The ~870 bp
fragment generated was reamplified by PCR using the primers 5' CCTACGTCTG
10 ACATGGAACA AAAATTGATA TCCGAAGAAG ATC-3' (olpb2F) and 5'-
CAGGCTCTAG ACTACTGGGC CGGCTGCAC-3' (olpb1R). The ~890 bp
fragment generated was then cleaved with Sal I and Xba I for insertion into
pFastBac™ HTc vector (Life Technologies, Gaithersburg, MD) between the Sal I
and Xba I sites for the generation of the plasmid pFB.LPAAT- β . This plasmid was
15 then transformed into *E. coli* DH10Bac™ (Life Technologies, Gaithersburg, MD) for
the generation of recombinant Bacmid DNA for transfection into HighFive
(Invitrogen, San Diego, CA) or Sf9 insect cells for the production of recombinant
Baculovirus stocks using the protocol described in the Bac-to-Bac® Baculovirus
Expression System (Life Technologies, Gaithersburg, MD), a eukaryotic
20 expression system for generating recombinant baculovirus through site-specific
transposition in *E. coli*. Viral stocks harvested from the transfected cells can then
be used to infect fresh insect cells for the subsequent expression of LPAAT- β
fusion protein with a poly-histidine tag and a myc-epitope near its N-terminus. The
membrane fraction from these Sf9 cells would be the source of LPAAT enzyme.

25 B. Preparation of cell membranes from Sf9 cells

For the preparation of membranes from Sf9 Cells, all steps are
performed on ice or at 4 °C. Sf9 cell pellets (~10⁸ cells) were thawed and
resuspended in 1-2 ml of buffer A (20 mM Hepes, pH 7.5, 1 mM DTT, 1 mM EDTA,
20% w/v glycerol, 1 mM Benzamidine, 1 µg/ml soybean trypsin inhibitor (SBTI),
30 1µg/ml pepstatin A) w/o DTT but with 1 mM Pefabloc. The cells were lysed by
sonication using a Branson Sonifier at output = 2, duty cycle = 2, 10 pulses each at
10s. with the tip of small sonicator probe submerged but not touching the walls.
DTT was then added to 1 mM from a 1 M stock. The samples were centrifuged at
1500 rpm for 5 min. The low speed supernatant was saved and centrifuged (TLA
35 100.3 rotor, polycarbonate tubes, 2 ml/tube or 1.5 ml/tube minimum) at 100000 x g

for 1 hr. The high speed pellet was resuspend in Buffer A with a probe sonicator (10 pulses @ output #2 and duty cycle 20%) as a source of LPAAT enzyme.

C. Assay of LPAAT- β Activity

- LPAAT- β catalyzes the transfer of an acyl group from a donor such as acyl-CoA to LPA. The transfer of the acyl group from acyl-CoA to LPA leads to the release of free CoA, which can be reacted with the thiol reagent, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB). The reaction between DTNB and the free sulfhydryl group from CoA generates a yellow-colored product, 3-carboxylato-4-nitrothiophenolate (CNP), that absorbs at 413 nm. LPAAT- β derived from Sf9 cell membrane overexpressing LPAAT- β were resuspended in HEPES saline buffer (20 mM HEPES pH 7.5, 150 mM NaCl), 1 mg/ml BSA and 72 μ l aliquots were distributed into 96-well microtiter plates. 8 μ l of compound of interest at 200 μ M dissolved in 100% DMSO was added into each well. 20 μ l of 1 mM 18:1-CoA and 1 mM sn-1-18:1 lysoPA was then added to each well to initiate the reaction and allowed to run at room temperature for 25 min. 100 μ l of 1 mM DTNB in 100% ethanol was then added to each well to quench the reaction and for color development. The absorbance at 405 nm, measured using a spectrophotometer plate reader, is proportional to the activity of LPAAT- β in the sample. This colorimetric assay was used for the high throughput screening of LPAAT inhibitors. Compounds that showed >50% inhibition of the change in absorbance at 405 nm compared to control were selected for a secondary assay.

- A secondary assay for LPAAT activity in cell extracts based on either the conversion of fluorescent NBD-LPA to NBD-PA (West, *et al.*, *DNA Cell Biol.* 6:691-701, 1997) or [14 C]LPA to [14 C]PA using TLC analysis was used to screen compounds that showed >50% inhibition of LPAAT activity in the primary colorimetric assay. The radiometric assay was carried out in Sf9 cell membrane overexpressing LPAAT- β resuspended in HEPES-saline buffer, pH 7.5, 1 mg/ml BSA, 1mM EDTA and 200 μ M [14 C]18:1-CoA and 200 μ M sn-1-18:1 lysoPA. The samples were incubated 7 min at 37 °C, extracted into organic solvent (CHCl₃ / CH₃OH / HCl at 33/66/1), before loading onto TLC plates. A more detailed protocol for the radiometric assay is described below:

Specifically, this LPAAT assay is a modification of the acyltransferase assay published previously (Hollenback and Glomset, *Biochemistry* 37:363-376 (1999)).






1. The basic assay, in a total volume of 50 μ l, employs a solution of substrates and the protein sample. Total assay volume, as well as the volume of each solution, can be changed to fit an experiment. In addition, other compounds, ex inhibitors and activators, can be included in the assay as well.
- 5 2. To prepare the solution of substrates:
 - a. Stocks of Hepes (pH 7.5), NaCl, EDTA, BSA and acyl-CoA (from Serdery or Sigma) are mixed with water to make the appropriate concentration of each compound. This can be varied from assay-to-assay, but the final reaction mix is about 50 mM Hepes, 100 mM NaCl, 1 mM EDTA, 1 mg/ml
10 BSA and 0-400 μ M acyl-CoA.
 - b. The lysoPA (from Avanti) is typically stored in chloroform and the 14 C-labeled acyl-CoA (from Amersham) is typically stored in water/ethanol=1:1. Appropriate amounts of each solution are added the to a 12 x 75 mm borosilicate glass test tube and dry the solvent under N_2 or Ar. An appropriate volume of the
15 solution prepared in 2a is added to the lysoPA and 14 C-labeled acyl-CoA. The lipids are resuspend by sonication for 15 sec in a bath sonicator. The resulting suspension is then incubated (with occasional gentle vortexing) for about 10 minutes at room temp. The *sn*-1-16:0 lysoPA may require brief warming of the solvent to solubilize it. The concentration of lysoPA and 14 C-labeled acyl-CoA can
20 vary, but typically the final lysoPA concentration ranges between 0 and 400 μ M and the 14 C-labeled acyl-CoA specific activity ranges between 0.5 and 2 Ci/mol.
3. Protein sample: varies from experiment-to-experiment.
4. The assay is performed by mixing the components in 12 x 75 mm borosilicate glass test tubes (the order of addition does not matter unless
25 indicated) and incubating at 37 °C for 5 to 10 minutes such that the assay within the linear range for time and protein.
5. The reaction is quenched by adding 1.3 ml of chloroform/methanol/HCl = 48/51/0.7 and vortexing. 10 μ l of carrier solution is then added (3 mg/ml each PA, ex. 16:0-18:1, and lysoPA, ex *sn*-1-18:1, in
30 chloroform). Two phases are formed by adding 0.3 ml of water to each tube and vortexing.
6. The sample is centrifuged for 3 minutes at 1000 x g, the upper (aqueous/methanol) phase is aspirated and the lower phase is dried under nitrogen.
- 35 7. Thin layer chromatography:






- a. The dried samples are resuspended in 50 μ l of chloroform and a 15 μ l aliquot is immediately spotted on an Analtech silica gel 60 HP-TLC plate (10 x 20 cm).
 - b. Plates are developed in chloroform/methanol/acetic acid/water = 85/12.5/12.5/3 (takes about 15 min) and dried.
 - c. To be able to convert pixel volume (determined by the Storm phosphor imager, see step 8b) into cpm, cpm standard curve must be generated on the plate. 14 C-labeled oleate dilutions in chloroform are made for this purpose. Four stocks (50 cpm/ μ l to 800 cpm/ μ l) are made and 2 μ l of a different concentration are spotted in each corner of the plate (where previously there was no radioactivity).
 - d. For quality control purposes, the plates are stained with primuline and scanned with the Storm (blue chemilluminescence mode).
- 15 The PA and lysoPA bands are easily detected in this system because of the carrier added in step 5. PA and lysoPA have respective R_f's of about 0.63 and 0.21.
8. Quantitating activity:
 - a. The plates are then wrapped in saran wrap and exposed to a
20 freshly blanked phosphor screen overnight (longer exposures can also be done to increase the signal).
 - b. The screens are scanned (Phosphorimager mode), and LPAAT activity is determined by quantifying the pixels in the band comigrating with PA standard versus the standard curve generated from the cpm standards that
25 were spotted in step 7c.

Table 1






	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
1		0.057	6-(5-Chloro-2-methoxyphenyl)-N-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine
2		2.30	6-(5-Chloro-2-methoxyphenyl)-N-phenyl-[1,3,5]triazine-2,4-diamine
3		0.022	6-(5-Chloro-2-methoxyphenyl)-N-(4-nitrophenyl)-[1,3,5]triazine-2,4-diamine
4		0.050	6-(2,5-Dichlorophenyl)-N-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine
5		0.280	N-Benzo[1,3]dioxol-5-yl-6-(5-chloro-2-methoxyphenyl)-[1,3,5]triazine-2,4-diamine






	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
6		0.230	N-(4-Chlorophenyl)-6-(2-fluoro-5-methoxyphenyl)-[1,3,5]triazine-2,4-diamine
7		0.140	6-(5-Chloro-2-ethoxyphenyl)-N-(4-Chlorophenyl)-[1,3,5]triazine-2,4-diamine
8		0.140	6-(5-Chloro-2-methoxyphenyl)-N-(3,4-dichlorophenyl)-[1,3,5]triazine-2,4-diamine
9		0.055	6-(5-Chloro-2-methylphenyl)-N-(4-Chlorophenyl)-[1,3,5]triazine-2,4-diamine
10		0.076	N-2-(4-Bromophenyl)-6-(5-chloro-2-methoxyphenyl)-[1,3,5]triazine-2,4-diamine






	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
11		0.060	N-2-(4-Bromophenyl)-6-(5-chloro-2-methylphenyl)-[1,3,5]triazine-2,4-diamine
12		0.070	N-2-(4-Bromophenyl)-6-(2,5-dichlorophenyl)-[1,3,5]triazine-2,4-diamine
13		0.055	6-(5-chloro-2-methylphenyl)-n-(1H-indazol-6-yl)-[1,3,5]triazine-2,4-diamine
14		0.250	N-(4-chlorophenyl)-6-(2,5-dimethylphenyl)-[1,3,5]triazine-2,4-diamine
15		0.430	6-(5-chloro-2-methoxyphenyl)-N-(4-fluorophenyl)-[1,3,5]triazine-2,4-diamine






	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
16		0.800	N-(4-chlorophenyl)-6-(3-chlorophenyl)- [1,3,5]triazine-2,4-diamine
17		1.00	N-(4-chlorophenyl)-6-(2,5-dimethoxyphenyl)- [1,3,5]triazine-2,4-diamine
18		prodrug	Poly-(L-glutamic acid) conjugate of 4-[4-chloro-6- (5-chloro-2-methyl-phenyl)- [1,3,5]-triazin-2-ylamino]- phenyl-methanol
19		0.2	N-Benzo[1,3]dioxol-5-yl-6- (5-chloro-2-methyl-phenyl)- [1,3,5]triazine-2,4-diamine
20		0.01	(4-Bromo-phenyl)-[4-chloro- 6-(5-chloro-2-methyl- phenyl)-[1,3,5]triazin-2-yl]- amine






	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
21		0.2	(4-Bromo-phenyl)-[4-(5-chloro-2-methyl-phenyl)-6-methoxy-[1,3,5]triazin-2-yl]-amine
22		0.013	[4-(5-Chloro-2-methyl-phenyl)-6-methyl-[1,3,5]triazin-2-yl]-(1H-indazol-6-yl)-amine
23		0.014	(4-Bromo-phenyl)-[4-(5-chloro-2-methyl-phenyl)-6-methyl-[1,3,5]triazin-2-yl]-amine
24		0.7	(4-Bromo-phenyl)-[4-(5-chloro-2-methyl-phenyl)-6-ethyl-[1,3,5]triazin-2-yl]-amine
25		10	6-(5-Chloro-2-methyl-phenyl)-N-(4-chloro-phenyl)-N-methyl-[1,3,5]triazine-2,4-diamine







	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
26		0.004	[4-Chloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-yl]-(1H-indazol-6-yl)-amine
27		2.7	[2-Aminimethyl-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-4-yl]-(4-bromo-phenyl)-amine
28		0.42	6-(5-Chloro-2-methyl-phenyl)-(4-bromo-phenyl)-[1,3,5]-triazine-2-carbonitrile
29		1.1	(4-Bromo-phenyl)-[4-(5-chloro-2-methyl-phenyl)-6-methylsulfanyl-[1,3,5]triazin-2-yl]-amine
30		0.01	[6-(5-Chloro-2-methyl-phenyl)-2-chloro-3-yl-[1,3,5]-triazin-4-yl]-(4-nitro-phenyl)-amine

	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
31		6	[6-(5-Chloro-2-methyl-phenyl)-2-piperidin-3-yl]-[1,3,5]triazin-4-yl)-(4-chloro-phenyl)-amine
32		10	6-(5-Chloro-2-methyl-phenyl)-N-(4-chloro-phenyl)-N,N-dimethyl-[1,3,5]triazine-2,4-diamine
33		0.24	[6-(5-Chloro-2-methyl-phenyl)-[1,3,5]triazin-4-yl]-(4-chloro-phenyl)-amine
34		0.16	N-(4-Chloro-3-methylamino-phenyl)-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine-2,4-diamine
35		0.13	[6-(5-Chloro-2-methyl-phenyl)-2-chloro-3-yl]-[1,3,5]-triazin-4-yl)-(4-azido-phenyl)-amine







	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
36		0.88	6-(5-Chloro-2-methyl-phenyl)-N-(4-azido-phenyl)-amino-[1,3,5]triazine-2,4-diamine
37		0.59	6-(5-Chloro-2-methyl-phenyl)-N-indan-5-yl-[1,3,5]triazine-2,4-diamine
38		1	6-(5-Chloro-2-methyl-phenyl)-N-(4-ethyl-phenyl)-[1,3,5]triazine-2,4-diamine
39		0.32	6-(5-Chloro-2-methyl-phenyl)-N-p-tolyl-[1,3,5]triazine-2,4-diamine
40		2.6	N-(4-bromophenyl)-6-(5-chloro-2-trifluoromethylphenyl)-[1,3,5]triazine-2,4-diamine

	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
41		0.15	{4-[4-Chloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-phenyl}-methanol
42		0.28	6-(5-Chloro-2-methyl-phenyl)-N-(4-ethynyl-phenyl)-[1,3,5]triazine-2,4-diamine
43		0.4	5-[4-amino-6-(5-chloro-2-methylphenyl)-[1,3,5]triazin-2-ylamino]-2-chloro-N-methylbenzamide
44		1.5	6-(5-chloro-2-methylaminophenyl)-N-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine
45		0.04	6-(5-Bromo-2-chloro-phenyl)-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine

	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
46		0.44	{4-[4-Amino-6-(2,5-dichlorophenyl)-[1,3,5]triazin-2-ylamino]-phenyl}-methanol
47		0.14	6-(5-chloro-2-dimethylaminophenyl)-N-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine
48		0.11	6-(2,5-Dichloro-phenyl)-N-(1H-indazol-6-yl)-[1,3,5]triazine-2,4-diamine
49		0.21	6-(2,5-Dichloro-phenyl)-N-p-tolyl-[1,3,5]triazine-2,4-diamine
50		0.2	N-(4-Chloro-phenyl)-6-(5-chloro-2-propoxy-phenyl)-[1,3,5]triazine-2,4-diamine






	Compound	LPAAT- β Cell-Free Assay (IC50, μ M)	Compound Name
51		0.6	6-(5-Chloro-2-ethoxy-phenyl)-N-(1H-indazol-6-yl)-[1,3,5]triazine-2,4-diamine
52		0.62	6-(5-Chloro-2-isopropoxy-phenyl)-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine
53		1.8	{4-[4-Amino-6-(5-chloro-2-ethoxy-phenyl)][1,3,5]triazin-2-ylamino}-phenyl)-methanol
54		0.12	6-(5-chloro-2-ethoxyphenyl)-N-(4-nitrophenyl)-[1,3,5]triazine-2,4-diamine
55		0.8	N-Benzo[1.3]dioxol-5-yl-6-(5-chloro-2-ethoxy-phenyl)[1,3,5]triazine-2,4-diamine
56		0.44	6-(5-Chloro-2-ethoxyphenyl)-N-(4-nitrophenyl)-[1,3,5]triazine-2,4-diamine






	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
57		0.14	2-{4-[4-Amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-phenyl}-ethanol
58		1.8	6-(5-Chloro-2-methyl-phenyl)-N-(4-dimethylaminomethyl-phenyl)-[1,3,5]triazine-2,4-diamine
59		0.4	6-(5-Chloro-2-methyl-phenyl)-N-(3,4-dimethyl-phenyl)-[1,3,5]triazine-2,4-diamine
60		1.3	{4-[4-Amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-phenyl}-acetic acid
61		2.3	6-(5-Chloro-2-ethoxyphenyl)-N-p-tolyl-[1,3,5]triazine-2,4-diamine
62		1	5-[4-amino-6-(5-chloro-2-ethoxyphenyl)-[1,3,5]triazin-2-ylamino]-2-chloro-N-methylbenzamide

	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
63		3.1 prodrug	(S)-2-Amino-pentanedioic acid 5-{4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl} ester
64		prodrug	(S)-2-Amino-pentanedioic acid 1-{4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl} ester
65		0.6	6-[5-Chloro-2-(2-methoxy-ethoxy)-phenyl]-N-(4-chloro-phenyl)[1,3,5]triazine-2,4-diamine
66		0.75	6-(5-Chloro-2-methyl-phenyl)-N-(3-ethyl-phenyl)-[1,3,5]triazine-2,4-diamine
67		0.71	6-(5-Chloro-2-methyl-phenyl)-N-(4-vinyl-phenyl)-[1,3,5] triazine-2,4-diamine
68		0.13	6-(5-Chloro-2-methyl-phenyl)-N-(4-fluoromethyl-phenyl)-[1,3,5]-triazine-2, 4-diamine

	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
69		2.6	1-{4-[4-Amino-6-(5-chloro-2-ethoxy-phenyl)-[1,3,5]triazin-2-ylamino]-phenyl}-ethane-1,2-diol
70		0.83 prodrug	Succinic acid mono- {4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl} ester
71		0.48 prodrug	Amino-acetic acid 4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl ester
72		1.4 prodrug	(S)-2-Amino-succinic acid 1-{4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl} ester
73		2.1 prodrug	(S)-2-Amino-succinic acid 4-{4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl} ester
74		0.68	{4-[4-(5-Chloro-2-methyl-phenyl)-6-methylamino-[1,3,5]triazin-2-ylamino]-phenyl}-methanol
75		0.97 prodrug	(S)-2-Amino-5-guanidino-pentanoic acid 4-[4-amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzyl ester

	Compound	LPAAT- β Cell-Free Assay (IC50, μ M)	Compound Name
76		10 prodrug	(S)-Pyrrolidine-2-carboxylic acid 4-[4-amino-6- (5-chloro-2-methyl-phenyl)-[1,3,5] triazin-2-ylamino]-benzyl ester
77		1.3 prodrug	2-Amino-propionic acid 4-[4-amino-6- (5-chloro-2-methyl-phenyl)-[1,3,5]-triazin-2-ylamino]-benzyl ester
78		0.64	6-(5-Chloro-2-methyl-phenyl)-N-(4-methoxy-methyl-phenyl)-[1,3,5]triazine-2,4-diamine
79		0.23	6-(5-Chloro-2-methoxy-phenyl)-N-p-tolyl-[1,3,5]triazine-2,4-diamine
80		0.14	6-(2-Bromo-5-chloro-phenyl)-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine

	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
81		0.1	N-(4-Chloro-phenyl)-6-(2-chloro-5-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine
82		0.3	N-Benzo[1,3]dioxol-5-yl-6-(2,5-dichloro-phenyl)-[1,3,5]triazine-2,4-diamine
83		0.18	6-(2-chloro-5-methyl-phenyl)-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine
84		0.1	[4-Chloro-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-yl]-(1H-indazol-5-yl)-amine
85		0.07	6-(5-chloro-2-fluoro-phenyl)-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine


	Compound	LPAAT- β Cell-Free Assay (IC ₅₀ , μ M)	Compound Name
86		0.45	6-(2-bromo-5-methyl-phenyl)-N-(4-chloro-phenyl)-[1,3,5]triazine-2,4-diamine
87		0.11	4-[4-Amino-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazin-2-ylamino]-benzaldehyde
88		0.18	N-(4-Chloromethyl-phenyl)-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine-2,4-diamine
89		0.1	4-[4-amino-6-(2,5-dichlorophenyl)-[1,3,5]triazin-2-ylamino]-benzonitrile
90		4.80	N-(3-chlorophenyl)-6-(2,5-dichlorophenyl)-[1,3,5]triazine-2,4-diamine

All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety.

- 5 From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

CLAIMS

1. A compound or physiologically acceptable salt thereof, wherein the compound has the formula:



wherein:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

R¹ is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;

R² is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;

R³ is H, alkyl, alkoxy, CCl₃, C≡N, NH₂, or SR where R and R' independently are alkyl;

R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R⁴ and R⁵ are taken together with the benzene ring to form a heterocycle or R⁴ and R⁵ are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached; and

with the proviso that R¹ and R² are not both Cl where R³ is NH₂ and Q is N;

with the proviso that R⁴ and R⁵ are not both H;

with the proviso that R⁴ is not OCH₃ or t-butyl where R¹ is Cl, R² is H, R³ is H, R⁵ is NH and Q is NH;

with the proviso that where one of R⁴ or R⁵ is H, the other is not CH₃, OCH₃, Cl, Br or NO₂ where R¹ is OH or OCH₃, R² is Cl, R³ is NH₂ and Q is NH;

with the proviso that R^4 and R^5 are not joined together to form naphthalene with the benzene ring to which R^4 and R^5 are attached where R^1 is OCH_3 or CH_2OH , R^2 is Cl, R^3 is NH_2 and Q is NH.

2. The compound or salt thereof of claim 1 wherein Q of the compound or salt thereof is NH.

3. The compound or salt thereof of claim 1 wherein R^4 or R^5 of the compound or salt thereof is acyl.

4. The compound or salt thereof of claim 1 wherein R^1 of the compound or salt thereof is alkyl, alkoxy or Cl.

5. The compound or salt thereof of claim 1 wherein R^2 of the compound or salt thereof is Cl.

6. The compound or salt thereof of claim 1 wherein R^3 of the compound or salt thereof is alkyl or NH_2 .

7. The compound or salt thereof of claim 1 wherein R^4 or R^5 of the compound or salt thereof is alkyl, Cl, Br, CF_3 , CH_2OH , $(CH_2)_2(CH_2)_2OH$, $N^*(=O)O^-$ or $C\equiv N$, or R^4 and R^5 are taken together with the benzene ring to form indazole.

8. The compound or salt thereof of claim 1 wherein the compound is any one of compounds 5-9, 11, 13-27, 29, 30, 33-45, 47, 50-73, 75-78, 80, 81 and 83-88 of Table 1, or physiologically acceptable salts thereof.

9. A pharmaceutical composition comprising a compound or salt thereof according to claim 1 in combination with a pharmaceutically acceptable carrier or diluent.

10. The pharmaceutical composition of claim 9 wherein Q of the compound or salt thereof is NH.

11. The pharmaceutical composition of claim 9 wherein R^4 or R^5 of the compound or salt thereof is acyl.

12. The pharmaceutical composition of claim 9 wherein R^1 of the compound or salt thereof is alkyl, alkoxy or Cl.


13. The pharmaceutical composition of claim 9 wherein R^2 of the compound or salt thereof is Cl.

14. The pharmaceutical composition of claim 9 wherein R^3 of the compound or salt thereof is alkyl or NH_2 .

15. The pharmaceutical composition of claim 9 wherein R^4 or R^5 of the compound or salt thereof is alkyl, Cl, Br, CF_3 , CH_2-OH , $(CH_2)_2-OH$, $N^+(=O)O^-$ or $C\equiv N$, or R^4 and R^5 are taken together with the benzene ring to form indazole.

16. The pharmaceutical composition of claim 9 wherein the compound is any one of compounds 5-9, 11, 13-27, 29, 30, 33-45, 47, 50-73, 75-78, 80, 81 and 83-88 of Table 1, or physiologically acceptable salts thereof.

17. A method for reducing the activity of lysophosphatidic acid acyltransferase β (LPAAT- β) comprising contacting LPAAT- β with a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to reduce LPAAT- β activity, wherein the compound has the formula:



wherein:

Q is NH , $N-(CH_2)_n$, $(CH_2)_n-N$, O , $O-(CH_2)_n$, $(CH_2)_n-O$, S , $S-(CH_2)_n$ or $(CH_2)_n-S$, where n is 1-10;

R^1 is H, OH, alkyl, alkoxy, Cl, F, Br, CR_3 where R_3 is Cl_3 , F_3 or Br_3 , NH_2 , NHR or NRR' where R and R' independently are alkyl;

R^2 is H, OH, alkyl, alkoxy, Cl, F, Br or CR_3 where R_3 is Cl_3 , F_3 or Br_3 ;

R^3 is H, alkyl, alkoxy, Cl, CCl_3 , $C\equiv N$, NH_2 , NHR , NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N;

R^4 and R^5 are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, $(CH_2)_n-OR$ where R is H or alkyl and n is 1-10, Cl, F, Br, CR_3 where R_3 is Cl_3 , F_3 or Br_3 , acyl, heterocycle, $N^*(=O)O^-$, $C\equiv N$, N_3 , SH, SR where R is alkyl, NH_2 , NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R^4 and R^5 are taken together with the benzene ring to form a heterocycle or R^4 and R^5 are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R^4 and R^5 are attached; and

with the proviso that R^1 and R^2 are not both Cl where R^3 is NH_2 and

Q is N.

18. The method of claim 17 wherein the LPAAT- β resides in an animal.

19. The method of claim 18 wherein the animal is a mammal.

20. The method of claim 17 wherein Q of the compound or salt thereof is NH.

21. The method of claim 17 wherein R^4 or R^5 of the compound or salt thereof is acyl.

22. The method of claim 17 wherein R^1 of the compound or salt thereof is alkyl, alkoxy or Cl.


23. The method of claim 17 wherein R^2 of the compound or salt thereof is Cl.

24. The method of claim 17 wherein R^3 of the compound or salt thereof is alkyl or NH_2 .

25. The method of claim 17 wherein R^4 or R^5 of the compound or salt thereof is alkyl, Cl, Br, CF_3 , CH_2-OH , $(CH_2)_2-OH$, $N^*(=O)O^-$ or $C\equiv N$, or R^4 and R^5 are taken together with the benzene ring to form indazole.

26. The method of claim 17 wherein the compound is any one of compounds 1-3, 5-11, 13-45, 47, 50-81 and 83-88 of Table 1, or physiologically acceptable salts thereof.

27. A method for inhibiting the proliferation of a cell in which the activity of lysophosphatidic acid acyltransferase β (LPAAT- β) is required for the proliferation of the cell comprising contacting the cell with a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to inhibit the proliferation of the cell, wherein the compound has the formula:



wherein:

Q is NH , $N-(CH_2)_n$, $(CH_2)_n-N$, O , $O-(CH_2)_n$, $(CH_2)_n-O$, S , $S-(CH_2)_n$ or $(CH_2)_n-S$, where n is 1-10;

R^1 is H , OH , alkyl, alkoxy, Cl , F , Br , CR_3 where R_3 is Cl_3 , F_3 or Br_3 , NH_2 , NHR or NRR' where R and R' independently are alkyl;

R^2 is H , OH , alkyl, alkoxy, Cl , F , Br or CR_3 where R_3 is Cl_3 , F_3 or Br_3 ;

R^3 is H , alkyl, alkoxy, Cl , CCl_3 , $C\equiv N$, NH_2 , NHR , NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N ;


R^4 and R^5 are independently H , OH , alkyl, alkenyl, alkynyl, alkoxy, $(CH_2)_n-OR$ where R is H or alkyl and n is 1-10, Cl , F , Br , CR_3 where R_3 is Cl_3 , F_3 or Br_3 , acyl, heterocycle, $N^*(=O)O^-$, $C\equiv N$, N_3 , SH , SR where R is alkyl, NH_2 , NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N , or R^4 and R^5 are taken together with the benzene ring to form a heterocycle or R^4 and R^5 are independently alkyl or alkenyl and joined together to

form a ring with the two carbon atoms of the benzene ring to which R^4 and R^5 are attached; and

with the proviso that R^1 and R^2 are not both Cl where R^3 is NH_2 and Q is N.

28. The method of claim 27 wherein the cell resides in an animal.
29. The method of claim 28 wherein the animal is a mammal.
30. The method of claim 27 wherein Q of the compound or salt thereof is NH.
31. The method of claim 27 wherein R^4 or R^5 of the compound or salt thereof is acyl.
32. The method of claim 27 wherein R^1 of the compound or salt thereof is alkyl, alkoxy or Cl.
33. The method of claim 27 wherein R^2 of the compound or salt thereof is Cl.
34. The method of claim 27 wherein R^3 of the compound or salt thereof is alkyl or NH_2 .
35. The method of claim 27 wherein R^4 or R^5 of the compound or salt thereof is alkyl, Cl, Br, CF_3 , CH_2-OH , $(CH_2)_2-OH$, $N^+(=O)O^-$ or $C\equiv N$, or R^4 and R^5 are taken together with the benzene ring to form indazole.
36. The method of claim 27 wherein the compound is any one of compounds 1-3, 5-11, 13-45, 47, 50-81 and 83-88 of Table 1, or physiologically acceptable salts thereof.
37. A method for treating a cancer in which lysophosphatidic acid acyltransferase β (LPAAT- β) activity is associated comprising administering to an animal in need, a compound or salt thereof, or in combination with a

pharmaceutically acceptable carrier or diluent, in an amount effective to treat the cancer, wherein the compound has the formula:



wherein:

Q is NH, N-(CH₂)_n, (CH₂)_n-N, O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n or (CH₂)_n-S, where n is 1-10;

R¹ is H, OH, alkyl, alkoxy, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, NH₂, NHR or NRR' where R and R' independently are alkyl;

R² is H, OH, alkyl, alkoxy, Cl, F, Br or CR₃ where R₃ is Cl₃, F₃ or Br₃;

R³ is H, alkyl, alkoxy, Cl, CCl₃, C≡N, NH₂, NHR, NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N;

R⁴ and R⁵ are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH₂)_n-OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR₃ where R₃ is Cl₃, F₃ or Br₃, acyl, heterocycle, N⁺(=O)O⁻, C≡N, N₃, SH, SR where R is alkyl, NH₂, NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R⁴ and R⁵ are taken together with the benzene ring to form a heterocycle or R⁴ and R⁵ are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R⁴ and R⁵ are attached; and

with the proviso that R¹ and R² are not both Cl where R³ is NH₂ and Q is N.

38. The method of claim 37 wherein the animal is a mammal.

39. The method of claim 37 wherein Q of the compound or salt thereof is NH.

40. The method of claim 37 wherein R⁴ or R⁵ of the compound or salt thereof is acyl.

41. The method of claim 37 wherein R^1 of the compound or salt thereof is alkyl, alkoxy or Cl.


42. The method of claim 37 wherein R^2 of the compound or salt thereof is Cl.

43. The method of claim 37 wherein R^3 of the compound or salt thereof is alkyl or NH_2 .

44. The method of claim 37 wherein R^4 or R^5 of the compound or salt thereof is alkyl, Cl, Br, CF_3 , CH_2-OH , $(CH_2)_2-OH$, $N^+(=O)O^-$ or $C\equiv N$, or R^4 and R^5 are taken together with the benzene ring to form indazole.

45. The method of claim 37 wherein the compound is any one of compounds 1-3, 5-11, 13-45, 47, 50-81 and 83-88 of Table 1, or physiologically acceptable salts thereof.

46. A coated medical device for inhibiting the proliferation of a cell in which the activity of lysophosphatidic acid acyltransferase β (LPAAT- β) is required for the proliferation of the cell comprising a medical device coated with a compound or salt thereof, or in combination with a pharmaceutically acceptable carrier or diluent, in an amount effective to inhibit the proliferation of the cell, wherein the compound has the formula:



wherein:

Q is NH , $N-(CH_2)_n$, $(CH_2)_n-N$, O , $O-(CH_2)_n$, $(CH_2)_n-O$, S , $S-(CH_2)_n$ or $(CH_2)_n-S$, where n is 1-10;

R^1 is H , OH , alkyl, alkoxy, Cl , F , Br , CR_3 where R_3 is Cl_3 , F_3 or Br_3 , NH_2 , NHR or NRR' where R and R' independently are alkyl;

R^2 is H , OH , alkyl, alkoxy, Cl , F , Br or CR_3 where R_3 is Cl_3 , F_3 or Br_3 ;

R^3 is H, alkyl, alkoxy, Cl, CCl_3 , $C\equiv N$, NH_2 , NHR , NRR' or SR where R and R' independently are alkyl, or R and R' are joined together to form a ring with the N;

R^4 and R^5 are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, $(CH_2)_n-OR$ where R is H or alkyl and n is 1-10, Cl, F, Br, CR_3 where R_3 is Cl_3 , F_3 or Br_3 , acyl, heterocycle, $N^*(=O)O^-$, $C\equiv N$, N_3 , SH, SR where R is alkyl, NH_2 , NHR or NRR' where R and R' independently are alkyl or are joined together to form a ring with the N, or R^4 and R^5 are taken together with the benzene ring to form a heterocycle or R^4 and R^5 are independently alkyl or alkenyl and joined together to form a ring with the two carbon atoms of the benzene ring to which R^4 and R^5 are attached; and

with the proviso that R^1 and R^2 are not both Cl where R^3 is NH_2 and Q is N.

47. The device of claim 46 wherein Q of the compound or salt thereof is NH.

48. The device of claim 46 wherein R^4 or R^5 of the compound or salt thereof is acyl.

49. The device of claim 46 wherein R^1 of the compound or salt thereof is alkyl, alkoxy or Cl.

50. The device of claim 46 wherein R^2 of the compound or salt thereof is Cl.

51. The device of claim 46 wherein R^3 of the compound or salt thereof is alkyl or NH_2 .

52. The device of claim 46 wherein R^4 or R^5 of the compound or salt thereof is alkyl, Cl, Br, CF_3 , CH_2-OH , $(CH_2)_2-OH$, $N^*(=O)O^-$ or $C\equiv N$, or R^4 and R^5 are taken together with the benzene ring to form indazole.

53. The device of claim 46 wherein the compound is any one of compounds 1-3, 5-11, 13-45, 47, 50-81 and 83-88 of Table 1, or physiologically acceptable salts thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/35256

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/53 C07D251/18 C07D251/16 C07D251/22 C07D405/12
C07D403/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 25780 A (SQUIBB BRISTOL MYERS CO) 11 May 2000 (2000-05-11) page 40, line 28 - line 29 page 42, line 28 - line 29 examples 103,106,109,138,199,204 claim 7, formula (VIII) claims 8,13,19,21 ---	1-53
X	WO 01 25220 A (KINETIX PHARM INC, AMGEN INC (US)) 12 April 2001 (2001-04-12) e.g. compounds with the RN: 333727-46-1, 333726-25-3, -21-9, -20-8 and 18-4 page 3, line 32 examples 11,13,14,165 --- -/--	1-53

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

5 February 2003

Date of mailing of the international search report

24/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cortés, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/35256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 22 26 474 A (KAKENYAKU KAKO KK (JP)) 22 February 1973 (1973-02-22) table 1, page 9, e.g. compounds M1613, M1813, M2113 page 18 -page 19 examples 3,15,32,47 claim 1 ---	1-16
X	EP 0 525 262 A (DAIKYO GOMU SEIKO KK (JP)) 3 February 1993 (1993-02-03) formula, page 3 e.g. compounds no. 2, 11, 17, 22, page 4 examples 3,8 ---	1-16
X	US 3 119 823 A (LOUIS FEEDMAN ET AL) 28 January 1964 (1964-01-28) formula I, column 1 last compound in table (I), column 2 ---	1-8
X	JP 49 069688 A (KAKEN JAKU KAO (JP)) 5 July 1974 (1974-07-05) & WPI-abstract e.g. compound with the RN: 53530-81-7 ---	1-8
X	JP 48 028486 A (KAKEN YAKU KAO KK (JP)) 14 April 1973 (1973-04-14) & WPI-abstract e.g. compound with the RN: 41243-04-3 ---	1-8
X	SU 274 102 A (BELYAKOV VK VINOGRADOV SV) 24 April 1970 (1970-04-24) formula in column 1 examples e.g. compounds with RN: 30718-87-7 and 24645-65-6 & WPI-abstract ---	1-8
X	DE 12 00 314 B (BAYER AG (D)) 9 September 1965 (1965-09-09) example 2 ---	1-8
X	FR 1 321 624 A (ICI LTD) 22 March 1963 (1963-03-22) example 1 ---	1-8

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/35256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BURMISTROV, S. I. ET AL: "6-Amino-4-arylamino-2-(o-hydroxyphenyl)triazines" retrieved from STN Database accession no. 61:47941 XP002230040 abstract & SU 162 150 1 (BURMISTROV, S. I.; FEDORINA, ZH. A.) 16 April 1964 (1964-04-16) e.g. compounds with RN: 100210-32-0, 97754-16-0 and 97740-57-3</p>	1-8
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BUDESINSKY, ZDENEK ET AL: "Substituted 2,4-diamino-6-phenyl-1,3,5-triazines" retrieved from STN Database accession no. 97:6328 XP002230041 e.g. compounds with the RN: 68215-93-0, -92-9, -91-8, -90-7, -89-4, -88-3, -87-2, -86-1, -85-0, -71-4, -70-3, -69-0, -68-9, -67-8 and -66-7 abstract & CS 193 949 B (CZECH.) 30 November 1979 (1979-11-30)</p>	1-16
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHAPIRO, SEYMOUR L. ET AL: "Guanamines. VIII. 6-(Substituted-phenyl)guanamines" retrieved from STN Database accession no. 56:60602 XP002230042 e.g. compound with the RN: 92907-66-9 abstract & J. ORG. CHEM. (1961), 26, 3331-4 ,</p> <p style="text-align: center;">-/-</p>	1-8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/35256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ELKAFAWY, A. F. ET AL: "Synthesis and reactions of some 4-aryl-2-benzylthio-1,6-dihydro-6-thiono- 1,3,5-triazines" retrieved from STN Database accession no. 115:279963 XP002230043 e.g. compounds with the RN: 35260-39-0, 34753-00-9 and 137538-83-1 abstract & PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS (1991), 62(1-4), 275-9,</p>	1-8
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YUKI, YASUO ET AL: "Preparation of amino-s-triazines with amino-or nitrophenyl groups" retrieved from STN Database accession no. 75:151765 XP002230044 e.g. compounds with the RN: 34095-21-1 and 34095-20-0 abstract & BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN (1971), 44(9), 2444-7 ,</p>	1-8
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, CHEN ET AL: "A Convenient Synthetic Method for Trisubstituted s-Triazines" retrieved from STN Database accession no. 124:146076 XP002230045 e.g. compounds with the RN: 173372-60-6 and 1773372-59-3 abstract & JOURNAL OF ORGANIC CHEMISTRY (1995), 60(26), 8428-30 ,</p>	1-8

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/35256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MOUSSA, G. E. M. ET AL: "Some reactions on 4-aryl-2-substituted amino-1,6-dihydro-6-thioxo-1,3,5- triazines" retrieved from STN Database accession no. 113:59112 XP002230046 e.g. compounds with RN: 128062-52-2 and 12862-51-1 abstract & JOURNAL OF THE CHEMICAL SOCIETY OF PAKISTAN (1989), 11(3), 194-9 ,</p>	1-8
X	<p>--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MICHALIK, MANFRED ET AL: "Synthesis of nitrogen-containing heterocycles" retrieved from STN Database accession no. 79:18680 XP002230047 e.g. compound with RN: 42010-50-4 abstract & WISSENSCHAFTLICHE ZEITSCHRIFT DER UNIVERSITAET ROSTOCK, MATHEMATISCH-NATURWISSENSCHAFTLICHE REIHE (1972), 21(2), 101-11 ,</p>	1-8
X	<p>--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BRODSKII, A. I. ET AL: "The mechanism underlying the action of secondary aromatic amine- type antioxidants and their ethers on the radiation oxidation of N-butylpropionamide and polycaproatide" retrieved from STN Database accession no. 69:3284 XP002230048 e.g. compound with RN: 17392-45-9 abstract & DOKLADY AKADEMII NAUK SSSR (1968), 179(2), 370-3 ,</p>	1-8
A	<p>--- US 5 856 331 A (SINGER JACK W ET AL) 5 January 1999 (1999-01-05) the whole document --- -/-</p>	1-53

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/35256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 02 36578 A (BONHAM LYNN (US)) 10 May 2002 (2002-05-10) the whole document -----	1-53

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 17-45 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1, 3-7, 9, 11-15, 17-19, 20-25, 27-29, 30-35, 37-38, 40-44, 46, 48-52 (partly)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

Consequently, the search has been restricted to compounds according to claim 1, wherein Q is NH, O or S and which are not excluded by the provisos of claim 1.

For reasons of conciseness, prior art disclosing only compounds excluded by the provisos of claim 1 (e.g. compounds with the RN: 178105-40-3, 173372-60-6, -59-3, 157458-26-9, 97706-58-6, 95025-44-8, 92969-27-2, 77007-97-7, 68215-85-0, -66-7, 34752-99-3, 52752-84-8, 3225-14-7) was not cited, except exemplarily D12 (CS 193949), which discloses some of the present examples (e.g. present examples 1-3, 10, 79).

It is noted, that many of the present examples are neither encompassed by present claim 1 nor novel (e.g. present examples 1-4, 10, 12, 46, 48, 49, 79, 82, 89, 90).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/35256

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.: —
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/35256

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0025780	A	11-05-2000	AU 1131500 A EP 1126843 A1 JP 2002528499 T WO 0025780 A1 US 6399773 B1 US 2002143176 A1	22-05-2000 29-08-2001 03-09-2002 11-05-2000 04-06-2002 03-10-2002
WO 0125220	A	12-04-2001	AU 1075401 A EP 1218360 A1 WO 0125220 A1	10-05-2001 03-07-2002 12-04-2001
DE 2226474	A	22-02-1973	GB 1390235 A JP 48026786 A JP 50011392 B CA 997762 A1 CA 1026336 A2 CH 573418 A5 DE 2226474 A1 DE 2265083 A1	09-04-1975 09-04-1973 30-04-1975 28-09-1976 14-02-1978 15-03-1976 22-02-1973 08-04-1976
EP 0525262	A	03-02-1993	JP 3190814 A EP 0525262 A1 US 5208012 A	20-08-1991 03-02-1993 04-05-1993
US 3119823	A	28-01-1964	NONE	
JP 49069688	A	05-07-1974	NONE	
JP 48028486	A	14-04-1973	JP 50017073 B	18-06-1975
SU 274102	A		NONE	
DE 1200314	B	09-09-1965	BE 654818 A CH 443322 A FR 1463793 A GB 1048990 A NL 6412451 A US 3277091 A	15-02-1965 15-09-1967 22-07-1966 23-11-1966 27-04-1965 04-10-1966
FR 1321624	A	22-03-1963	NONE	
SU 162150	1		NONE	
CS 193949	B	30-11-1979	CS 193949 B1	30-11-1979
US 5856331	A	05-01-1999	AU 1090795 A EP 0728003 A1 WO 9513075 A1	29-05-1995 28-08-1996 18-05-1995
WO 0236578	A	10-05-2002	AU 1665002 A WO 0236578 A2 US 2002103195 A1	15-05-2002 10-05-2002 01-08-2002